cancer_type,TMB (FMOne mutation burden per MB),Neoantigen burden per MB,Immune phenotype,response_label,user_question,full_query
BLCA,18.0,4.68627451,excluded,NR,"In a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 18.0 and mRNA TPM expression analysis from a bladder biopsy characterizing the tumor immune microenvironment, how likely is it that he will respond to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 18.0 and mRNA TPM expression analysis from a bladder biopsy characterizing the tumor immune microenvironment, how likely is it that he will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0257bb-ar-0257bbb.pkl. "
BLCA,1.0,0.31372549,desert,NR,"For a male patient with bladder urothelial carcinoma who underwent a bladder biopsy with mRNA TPM expression profiling to assess the tumor immune microenvironment and exhibits a tumor mutational burden of 1.0, would treatment with Atezolizumab likely be effective?","For a male patient with bladder urothelial carcinoma who underwent a bladder biopsy with mRNA TPM expression profiling to assess the tumor immune microenvironment and exhibits a tumor mutational burden of 1.0, would treatment with Atezolizumab likely be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/025b45-ar-025b45c.pkl. "
BLCA,44.0,6.196078431,inflamed,NR,"For a female patient with bladder urothelial carcinoma who has been evaluated using mRNA TPM expression from a bladder biopsy to characterize the tumor immune microenvironment and has a tumor mutational burden of 44.0, how likely is she to benefit from treatment with atezolizumab?","For a female patient with bladder urothelial carcinoma who has been evaluated using mRNA TPM expression from a bladder biopsy to characterize the tumor immune microenvironment and has a tumor mutational burden of 44.0, how likely is she to benefit from treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/032c64-ar-032c642.pkl. "
BLCA,2.0,1.470588235,excluded,NR,"In a female patient with bladder urothelial carcinoma, a lymph node biopsy indicated mRNA TPM expression reflective of the tumor's immune microenvironment, and the tumor mutational burden is 2.0. Based on these findings, would you anticipate that treatment with Atezolizumab is likely to be effective?","In a female patient with bladder urothelial carcinoma, a lymph node biopsy indicated mRNA TPM expression reflective of the tumor's immune microenvironment, and the tumor mutational burden is 2.0. Based on these findings, would you anticipate that treatment with Atezolizumab is likely to be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0571f1-ar-0571f17.pkl. "
BLCA,8.0,,inflamed,R,"For a male patient with bladder urothelial carcinoma, whose biopsy shows mRNA TPM expression data of the tumor immune microenvironment and a tumor mutational burden of 8.0, would treatment with Atezolizumab be expected to yield a beneficial response?","For a male patient with bladder urothelial carcinoma, whose biopsy shows mRNA TPM expression data of the tumor immune microenvironment and a tumor mutational burden of 8.0, would treatment with Atezolizumab be expected to yield a beneficial response?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/065890-ar-0658907.pkl. "
BLCA,6.0,0.921568627,,R,"I have a female patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was characterized using mRNA TPM expression from a bladder biopsy. With a tumor mutational burden of 6.0, do these factors indicate that she is likely to respond favorably to Atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was characterized using mRNA TPM expression from a bladder biopsy. With a tumor mutational burden of 6.0, do these factors indicate that she is likely to respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0684af-ar-0684af7.pkl. "
BLCA,11.0,0.745098039,excluded,R,"For a male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 11.0 and whose mRNA TPM expression was assessed via kidney biopsy to evaluate the tumor immune microenvironment, how likely is he to respond to treatment with atezolizumab?","For a male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 11.0 and whose mRNA TPM expression was assessed via kidney biopsy to evaluate the tumor immune microenvironment, how likely is he to respond to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/075e03-ar-075e037.pkl. "
BLCA,18.0,2.117647059,excluded,R,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression was measured from a bladder biopsy to evaluate the tumor immune microenvironment, and the tumor mutational burden is 18.0. Based on these findings, how likely is it that the patient will respond to atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression was measured from a bladder biopsy to evaluate the tumor immune microenvironment, and the tumor mutational burden is 18.0. Based on these findings, how likely is it that the patient will respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/07a93a-ar-07a93a2.pkl. "
BLCA,,,excluded,NR,"I have a female patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression from a bladder biopsy, and her tumor mutational burden (TMB) is reported as 'nan.' Based on these findings, is she likely to benefit from treatment with Atezolizumab?","I have a female patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression from a bladder biopsy, and her tumor mutational burden (TMB) is reported as 'nan.' Based on these findings, is she likely to benefit from treatment with Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/08cce2-ar-08cce2f.pkl. "
BLCA,,,inflamed,NR,"I am evaluating a male patient with bladder urothelial carcinoma who underwent mRNA TPM expression analysis from a nan biopsy to assess the tumor immune microenvironment, and his tumor mutational burden is reported as nan. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?","I am evaluating a male patient with bladder urothelial carcinoma who underwent mRNA TPM expression analysis from a nan biopsy to assess the tumor immune microenvironment, and his tumor mutational burden is reported as nan. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/09c84e-ar-09c84ec.pkl. "
BLCA,2.0,0.215686275,,NR,"I have a male patient with bladder urothelial carcinoma and a tumor mutational burden of 2.0. mRNA TPM expression was measured from a kidney biopsy to evaluate the tumor immune microenvironment. Given these parameters, how likely is it that the patient will respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma and a tumor mutational burden of 2.0. mRNA TPM expression was measured from a kidney biopsy to evaluate the tumor immune microenvironment. Given these parameters, how likely is it that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0a0f2b-ar-0a0f2ba.pkl. "
BLCA,8.0,1.274509804,excluded,NR,"For a patient with bladder urothelial carcinoma, whose bladder biopsy was analyzed for mRNA TPM expression to evaluate the tumor immune microenvironment and who has a tumor mutational burden of 8.0, would treatment with atezolizumab likely lead to a favorable response?","For a patient with bladder urothelial carcinoma, whose bladder biopsy was analyzed for mRNA TPM expression to evaluate the tumor immune microenvironment and who has a tumor mutational burden of 8.0, would treatment with atezolizumab likely lead to a favorable response?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0a7c20-ar-0a7c209.pkl. "
BLCA,,,,NR,"For a female patient with bladder urothelial carcinoma, whose lymph node biopsy provided mRNA TPM expression data for assessing the tumor immune microenvironment but with unavailable tumor mutational burden information, would treatment with Atezolizumab likely be effective?","For a female patient with bladder urothelial carcinoma, whose lymph node biopsy provided mRNA TPM expression data for assessing the tumor immune microenvironment but with unavailable tumor mutational burden information, would treatment with Atezolizumab likely be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0bdb34-ar-0bdb342.pkl. "
BLCA,9.0,,excluded,NR,"I have a male patient with bladder urothelial carcinoma (BLCA) who underwent a ureter biopsy for mRNA TPM expression profiling to assess the tumor immune microenvironment. With a tumor mutational burden (TMB) of 9.0, how likely is the patient to respond favorably to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma (BLCA) who underwent a ureter biopsy for mRNA TPM expression profiling to assess the tumor immune microenvironment. With a tumor mutational burden (TMB) of 9.0, how likely is the patient to respond favorably to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0ce9c9-ar-0ce9c98.pkl. "
BLCA,4.0,0.137254902,desert,NR,"I have a female patient with bladder urothelial carcinoma who has undergone a bladder biopsy. Her mRNA TPM expression has been assessed to evaluate the tumor immune microenvironment, and her tumor mutational burden is 4.0. Given these findings, how likely is she to respond to treatment with Atezolizumab?","I have a female patient with bladder urothelial carcinoma who has undergone a bladder biopsy. Her mRNA TPM expression has been assessed to evaluate the tumor immune microenvironment, and her tumor mutational burden is 4.0. Given these findings, how likely is she to respond to treatment with Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0d855c-ar-0d855cf.pkl. "
BLCA,32.0,4.098039216,excluded,NR,"For a patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 32.0 and mRNA TPM expression data from a ureter biopsy evaluating the tumor immune microenvironment, how likely is the patient to respond to treatment with Atezolizumab?","For a patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 32.0 and mRNA TPM expression data from a ureter biopsy evaluating the tumor immune microenvironment, how likely is the patient to respond to treatment with Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0f956e-ar-0f956e7.pkl. "
BLCA,21.0,3.529411765,desert,NR,"I have a male patient with bladder urothelial carcinoma whose bladder biopsy analysis showed an mRNA TPM profile of the tumor immune microenvironment and a tumor mutational burden of 21.0. Considering treatment with atezolizumab, what is the likelihood that he will respond favorably to this therapy?","I have a male patient with bladder urothelial carcinoma whose bladder biopsy analysis showed an mRNA TPM profile of the tumor immune microenvironment and a tumor mutational burden of 21.0. Considering treatment with atezolizumab, what is the likelihood that he will respond favorably to this therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/110501-ar-110501d.pkl. "
BLCA,10.0,1.078431373,inflamed,NR,"I have a male patient diagnosed with bladder urothelial carcinoma (BLCA) with a tumor mutational burden of 10 mutations per megabase. mRNA TPM expression profiling of the tumor immune microenvironment was performed using a kidney biopsy sample. Based on these findings, what is the likelihood that he will respond to treatment with atezolizumab?","I have a male patient diagnosed with bladder urothelial carcinoma (BLCA) with a tumor mutational burden of 10 mutations per megabase. mRNA TPM expression profiling of the tumor immune microenvironment was performed using a kidney biopsy sample. Based on these findings, what is the likelihood that he will respond to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/12502d-ar-12502d9.pkl. "
BLCA,38.0,6.68627451,desert,R,For a patient with bladder urothelial carcinoma who has a tumor mutational burden of 38.0—and whose mRNA TPM expression from a bladder biopsy has been used to characterize the tumor immune microenvironment—would these findings suggest that treatment with Atezolizumab is likely to be effective?,For a patient with bladder urothelial carcinoma who has a tumor mutational burden of 38.0—and whose mRNA TPM expression from a bladder biopsy has been used to characterize the tumor immune microenvironment—would these findings suggest that treatment with Atezolizumab is likely to be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/149386-ar-1493861.pkl. 
BLCA,7.0,0.568627451,excluded,R,"I have a female patient with bladder urothelial carcinoma who underwent a bladder biopsy with mRNA TPM expression analysis to assess the tumor immune microenvironment. Her tumor mutational burden is 7.0. Based on these parameters, is she likely to respond favorably to Atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma who underwent a bladder biopsy with mRNA TPM expression analysis to assess the tumor immune microenvironment. Her tumor mutational burden is 7.0. Based on these parameters, is she likely to respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/14df63-ar-14df63a.pkl. "
BLCA,5.0,0.274509804,excluded,NR,"We have a male patient with bladder urothelial carcinoma who underwent a bladder biopsy with mRNA TPM expression profiling to evaluate the tumor immune microenvironment. Given that his tumor mutational burden is 5.0, would Atezolizumab be an appropriate therapeutic option in this case?","We have a male patient with bladder urothelial carcinoma who underwent a bladder biopsy with mRNA TPM expression profiling to evaluate the tumor immune microenvironment. Given that his tumor mutational burden is 5.0, would Atezolizumab be an appropriate therapeutic option in this case?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/166a41-ar-166a419.pkl. "
BLCA,15.0,,desert,NR,"For a male patient with bladder urothelial carcinoma who has undergone mRNA TPM expression profiling from a bladder biopsy, and who presents with a tumor mutational burden of 15.0, what is the likelihood that he will respond favorably to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma who has undergone mRNA TPM expression profiling from a bladder biopsy, and who presents with a tumor mutational burden of 15.0, what is the likelihood that he will respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/180398-ar-1803982.pkl. "
BLCA,,0.215686275,excluded,NR,"I have a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression data from a kidney biopsy, although the tumor mutational burden is not available. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression data from a kidney biopsy, although the tumor mutational burden is not available. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/181b63-ar-181b638.pkl. "
BLCA,,,,NR,"In a male patient with bladder urothelial carcinoma, mRNA expression analysis (TPM) was performed on a lung biopsy to evaluate the tumor immune microenvironment, and the tumor mutational burden is unavailable. Based on these findings, how likely is the patient to respond to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA expression analysis (TPM) was performed on a lung biopsy to evaluate the tumor immune microenvironment, and the tumor mutational burden is unavailable. Based on these findings, how likely is the patient to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/187e05-ar-187e056.pkl. "
BLCA,18.0,2.039215686,excluded,NR,"In a patient with bladder urothelial carcinoma, where mRNA TPM expression from a bladder biopsy has been used to profile the tumor immune microenvironment and the tumor mutational burden is 18.0, how likely is it that the patient will respond favorably to Atezolizumab therapy?","In a patient with bladder urothelial carcinoma, where mRNA TPM expression from a bladder biopsy has been used to profile the tumor immune microenvironment and the tumor mutational burden is 18.0, how likely is it that the patient will respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/18a4da-ar-18a4dab.pkl. "
BLCA,7.0,0.392156863,inflamed,NR,"I have a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 7.0, and we obtained mRNA TPM expression data from a ureter biopsy to assess the tumor immune microenvironment. Given this information, can we predict whether he is likely to respond to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 7.0, and we obtained mRNA TPM expression data from a ureter biopsy to assess the tumor immune microenvironment. Given this information, can we predict whether he is likely to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/18b935-ar-18b9351.pkl. "
BLCA,19.0,1.803921569,,NR,"I am evaluating a male patient with bladder urothelial carcinoma whose tumor biopsy has been analyzed for mRNA TPM expression to assess the tumor immune microenvironment, and the tumor mutational burden is 19.0. Given these findings, what is the likelihood that the patient will benefit from treatment with atezolizumab?","I am evaluating a male patient with bladder urothelial carcinoma whose tumor biopsy has been analyzed for mRNA TPM expression to assess the tumor immune microenvironment, and the tumor mutational burden is 19.0. Given these findings, what is the likelihood that the patient will benefit from treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/18bc10-ar-18bc107.pkl. "
BLCA,5.0,0.470588235,excluded,NR,"In a patient with bladder urothelial carcinoma, where bladder biopsy analysis reveals mRNA TPM expression data of the tumor immune microenvironment and a tumor mutational burden of 5.0, what is the likelihood that treatment with Atezolizumab will be effective?","In a patient with bladder urothelial carcinoma, where bladder biopsy analysis reveals mRNA TPM expression data of the tumor immune microenvironment and a tumor mutational burden of 5.0, what is the likelihood that treatment with Atezolizumab will be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/18be5b-ar-18be5b3.pkl. "
BLCA,5.0,0.431372549,excluded,NR,"In a patient with bladder urothelial carcinoma, whose mRNA TPM expression was analyzed from a bladder biopsy to assess the tumor immune microenvironment and who has a tumor mutational burden of 5.0, how likely is it that treatment with atezolizumab would be effective?","In a patient with bladder urothelial carcinoma, whose mRNA TPM expression was analyzed from a bladder biopsy to assess the tumor immune microenvironment and who has a tumor mutational burden of 5.0, how likely is it that treatment with atezolizumab would be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/19fec8-ar-19fec8f.pkl. "
BLCA,8.0,1.176470588,excluded,NR,"For a male patient with bladder urothelial carcinoma, whose tumor mutational burden is 8.0 and mRNA TPM expression has been assessed from a bladder biopsy to characterize the tumor immune microenvironment, would you expect a favorable response to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma, whose tumor mutational burden is 8.0 and mRNA TPM expression has been assessed from a bladder biopsy to characterize the tumor immune microenvironment, would you expect a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1a87df-ar-1a87df7.pkl. "
BLCA,13.0,0.294117647,desert,NR,"For a female patient with bladder urothelial carcinoma (BLCA) who underwent a ureter biopsy for mRNA TPM expression analysis of the tumor immune microenvironment, and with a tumor mutational burden (TMB) of 13.0, how likely is it that the patient will respond favorably to Atezolizumab?","For a female patient with bladder urothelial carcinoma (BLCA) who underwent a ureter biopsy for mRNA TPM expression analysis of the tumor immune microenvironment, and with a tumor mutational burden (TMB) of 13.0, how likely is it that the patient will respond favorably to Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1ab1b2-ar-1ab1b28.pkl. "
BLCA,16.0,1.862745098,excluded,R,"For a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 16.0 and mRNA TPM expression measured from a kidney biopsy to assess the immune microenvironment, what is the likelihood of a favorable response to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 16.0 and mRNA TPM expression measured from a kidney biopsy to assess the immune microenvironment, what is the likelihood of a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1abf01-ar-1abf01d.pkl. "
BLCA,2.0,0.647058824,excluded,NR,"I have a patient with bladder urothelial carcinoma who underwent a kidney biopsy for mRNA TPM expression analysis to evaluate the tumor immune microenvironment, and their tumor mutational burden is 2.0. Based on these findings, is treatment with atezolizumab likely to be effective?","I have a patient with bladder urothelial carcinoma who underwent a kidney biopsy for mRNA TPM expression analysis to evaluate the tumor immune microenvironment, and their tumor mutational burden is 2.0. Based on these findings, is treatment with atezolizumab likely to be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1ac4e3-ar-1ac4e3d.pkl. "
BLCA,,,excluded,NR,For a female patient with bladder urothelial carcinoma who has had mRNA TPM expression measured from a bladder biopsy to evaluate the tumor immune microenvironment—and with tumor mutational burden data unavailable—how likely is she to respond to treatment with Atezolizumab?,For a female patient with bladder urothelial carcinoma who has had mRNA TPM expression measured from a bladder biopsy to evaluate the tumor immune microenvironment—and with tumor mutational burden data unavailable—how likely is she to respond to treatment with Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1c0ecf-ar-1c0ecfb.pkl. 
BLCA,7.0,0.549019608,excluded,NR,"I have a male patient with bladder urothelial carcinoma whose biopsy mRNA TPM expression was analyzed to assess the tumor immune microenvironment. The tumor mutational burden (TMB) is 7.0. Given these findings, what is the likelihood that the patient will respond to treatment with atezolizumab?","I have a male patient with bladder urothelial carcinoma whose biopsy mRNA TPM expression was analyzed to assess the tumor immune microenvironment. The tumor mutational burden (TMB) is 7.0. Given these findings, what is the likelihood that the patient will respond to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1c8b08-ar-1c8b086.pkl. "
BLCA,20.0,4.019607843,desert,NR,"I have a male patient with bladder urothelial carcinoma whose bladder biopsy showed specific mRNA TPM expression metrics evaluating the tumor immune microenvironment, and his tumor mutational burden is 20.0. Given these findings, how likely is he to benefit from treatment with atezolizumab?","I have a male patient with bladder urothelial carcinoma whose bladder biopsy showed specific mRNA TPM expression metrics evaluating the tumor immune microenvironment, and his tumor mutational burden is 20.0. Given these findings, how likely is he to benefit from treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1dda30-ar-1dda30f.pkl. "
BLCA,5.0,1.431372549,inflamed,NR,"I have a female patient with bladder urothelial carcinoma whose tumor mRNA TPM expression levels were evaluated via biopsy to assess the immune microenvironment. Her tumor mutational burden is 5.0. Given these factors, how likely is she to respond to Atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma whose tumor mRNA TPM expression levels were evaluated via biopsy to assess the immune microenvironment. Her tumor mutational burden is 5.0. Given these factors, how likely is she to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1e9c4d-ar-1e9c4d1.pkl. "
BLCA,38.0,4.509803922,inflamed,R,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression profiling of a bladder biopsy was performed to evaluate the tumor immune microenvironment, and the tumor mutational burden was determined to be 38.0. Based on these findings, what is the likelihood of a favorable response to atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression profiling of a bladder biopsy was performed to evaluate the tumor immune microenvironment, and the tumor mutational burden was determined to be 38.0. Based on these findings, what is the likelihood of a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1f66db-ar-1f66db5.pkl. "
BLCA,6.0,0.549019608,desert,NR,"I'm managing a male patient with bladder urothelial carcinoma whose kidney biopsy, performed to evaluate the tumor immune microenvironment, revealed mRNA TPM expression and a tumor mutational burden of 6.0. Given these findings, is he likely to benefit from treatment with atezolizumab?","I'm managing a male patient with bladder urothelial carcinoma whose kidney biopsy, performed to evaluate the tumor immune microenvironment, revealed mRNA TPM expression and a tumor mutational burden of 6.0. Given these findings, is he likely to benefit from treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1f83eb-ar-1f83ebd.pkl. "
BLCA,8.0,1.235294118,inflamed,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression profiling from a bladder biopsy was used to characterize the tumor immune microenvironment, and his tumor mutational burden is 8.0 mutations per megabase. Given these factors, how likely is it that he will respond to atezolizumab treatment?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression profiling from a bladder biopsy was used to characterize the tumor immune microenvironment, and his tumor mutational burden is 8.0 mutations per megabase. Given these factors, how likely is it that he will respond to atezolizumab treatment?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1fa6bc-ar-1fa6bcb.pkl. "
BLCA,13.0,2.392156863,inflamed,R,"For a male patient with bladder urothelial carcinoma evaluated via a bladder biopsy showing mRNA TPM expression and a tumor mutational burden of 13.0, based on these immunological and molecular characteristics, would you expect a favorable response to treatment with atezolizumab?","For a male patient with bladder urothelial carcinoma evaluated via a bladder biopsy showing mRNA TPM expression and a tumor mutational burden of 13.0, based on these immunological and molecular characteristics, would you expect a favorable response to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/203dcf-ar-203dcf1.pkl. "
BLCA,5.0,0.294117647,excluded,NR,"In a male patient with bladder urothelial carcinoma, a kidney biopsy revealed mRNA TPM expression data for the tumor immune microenvironment and a tumor mutational burden of 5.0. How might these factors influence his likelihood of responding to Atezolizumab?","In a male patient with bladder urothelial carcinoma, a kidney biopsy revealed mRNA TPM expression data for the tumor immune microenvironment and a tumor mutational burden of 5.0. How might these factors influence his likelihood of responding to Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2070b4-ar-2070b41.pkl. "
BLCA,5.0,0.235294118,desert,NR,"In a female patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 5.0 and mRNA TPM expression data from a bladder biopsy evaluating the tumor immune microenvironment, how predictive are these factors of a favorable response to Atezolizumab therapy?","In a female patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 5.0 and mRNA TPM expression data from a bladder biopsy evaluating the tumor immune microenvironment, how predictive are these factors of a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/230959-ar-2309593.pkl. "
BLCA,5.0,0.333333333,excluded,NR,"In a female patient with bladder urothelial carcinoma, mRNA TPM expression from a kidney biopsy was used to evaluate the tumor immune microenvironment, and her tumor mutational burden is 5.0. Based on these findings, what is the likelihood of her responding to Atezolizumab therapy?","In a female patient with bladder urothelial carcinoma, mRNA TPM expression from a kidney biopsy was used to evaluate the tumor immune microenvironment, and her tumor mutational burden is 5.0. Based on these findings, what is the likelihood of her responding to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/23aa15-ar-23aa15d.pkl. "
BLCA,,1.823529412,desert,R,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression from an alternate biopsy was used to assess the tumor immune microenvironment, but the tumor mutational burden (TMB) value is reported as 'nan.' Given these factors, how likely is the patient to respond to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression from an alternate biopsy was used to assess the tumor immune microenvironment, but the tumor mutational burden (TMB) value is reported as 'nan.' Given these factors, how likely is the patient to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/25510f-ar-25510f3.pkl. "
BLCA,12.0,1.529411765,inflamed,R,"In a female patient with bladder urothelial carcinoma, who has a tumor mutational burden of 12.0 and mRNA TPM expression data from a lymph node biopsy assessing the tumor immune microenvironment, what is the likelihood of a favorable response to Atezolizumab therapy?","In a female patient with bladder urothelial carcinoma, who has a tumor mutational burden of 12.0 and mRNA TPM expression data from a lymph node biopsy assessing the tumor immune microenvironment, what is the likelihood of a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2570ff-ar-2570ff4.pkl. "
BLCA,1.0,0.274509804,excluded,NR,"In a patient with bladder urothelial carcinoma who underwent mRNA TPM profiling from a bladder biopsy to characterize the tumor immune microenvironment and has a tumor mutational burden of 1.0, would these findings predict a favorable response to Atezolizumab therapy?","In a patient with bladder urothelial carcinoma who underwent mRNA TPM profiling from a bladder biopsy to characterize the tumor immune microenvironment and has a tumor mutational burden of 1.0, would these findings predict a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/26104d-ar-26104d5.pkl. "
BLCA,6.0,0.431372549,excluded,NR,"For a male patient with bladder urothelial carcinoma, whose bladder biopsy revealed specific mRNA TPM expression patterns and a tumor mutational burden of 6.0, how likely is it that treatment with atezolizumab will be effective?","For a male patient with bladder urothelial carcinoma, whose bladder biopsy revealed specific mRNA TPM expression patterns and a tumor mutational burden of 6.0, how likely is it that treatment with atezolizumab will be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/262422-ar-2624229.pkl. "
BLCA,8.0,0.745098039,excluded,R,"In a female patient with bladder urothelial carcinoma and a tumor mutational burden of 8.0, where mRNA TPM expression data from a bladder biopsy have been used to characterize the tumor immune microenvironment, what is the likelihood that she will respond to Atezolizumab therapy?","In a female patient with bladder urothelial carcinoma and a tumor mutational burden of 8.0, where mRNA TPM expression data from a bladder biopsy have been used to characterize the tumor immune microenvironment, what is the likelihood that she will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/27299a-ar-27299ae.pkl. "
BLCA,6.0,0.568627451,inflamed,NR,"I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was measured from a kidney biopsy to assess the tumor immune microenvironment, and the tumor mutational burden is 6.0. Based on these parameters, is he likely to respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was measured from a kidney biopsy to assess the tumor immune microenvironment, and the tumor mutational burden is 6.0. Based on these parameters, is he likely to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/286870-ar-2868703.pkl. "
BLCA,22.0,,desert,NR,"In a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 22 and mRNA TPM expression measurements from a bladder biopsy for tumor immune microenvironment assessment, would he be expected to respond to Atezolizumab treatment?","In a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 22 and mRNA TPM expression measurements from a bladder biopsy for tumor immune microenvironment assessment, would he be expected to respond to Atezolizumab treatment?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/28e603-ar-28e6031.pkl. "
BLCA,1.0,,excluded,NR,"I have a male patient with bladder urothelial carcinoma. His bladder biopsy revealed mRNA TPM expression for assessment of the tumor immune microenvironment, and his tumor mutational burden is 1.0. Based on these findings, how likely is he to respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma. His bladder biopsy revealed mRNA TPM expression for assessment of the tumor immune microenvironment, and his tumor mutational burden is 1.0. Based on these findings, how likely is he to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/297c03-ar-297c030.pkl. "
BLCA,,0.490196078,desert,NR,"I have a female patient with bladder urothelial carcinoma who underwent a ureter biopsy for mRNA TPM expression profiling to assess the tumor immune microenvironment. The tumor mutational burden (TMB) data is unavailable. Considering treatment with Atezolizumab, what is the likelihood that the patient will respond favorably to this therapy?","I have a female patient with bladder urothelial carcinoma who underwent a ureter biopsy for mRNA TPM expression profiling to assess the tumor immune microenvironment. The tumor mutational burden (TMB) data is unavailable. Considering treatment with Atezolizumab, what is the likelihood that the patient will respond favorably to this therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/29da92-ar-29da928.pkl. "
BLCA,2.0,0.156862745,desert,NR,"Given a male patient with bladder urothelial carcinoma whose mRNA TPM expression was evaluated from a kidney biopsy to characterize the tumor immune microenvironment, and who has a tumor mutational burden of 2.0, how likely is it that he will respond to Atezolizumab therapy?","Given a male patient with bladder urothelial carcinoma whose mRNA TPM expression was evaluated from a kidney biopsy to characterize the tumor immune microenvironment, and who has a tumor mutational burden of 2.0, how likely is it that he will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2b672f-ar-2b672f4.pkl. "
BLCA,11.0,1.294117647,excluded,NR,"I have a male patient with bladder urothelial carcinoma whose bladder biopsy revealed specific mRNA TPM expression levels to assess the tumor immune microenvironment. The tumor mutational burden is 11.0. Considering these factors, is the patient likely to benefit from treatment with atezolizumab?","I have a male patient with bladder urothelial carcinoma whose bladder biopsy revealed specific mRNA TPM expression levels to assess the tumor immune microenvironment. The tumor mutational burden is 11.0. Considering these factors, is the patient likely to benefit from treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2bba8c-ar-2bba8cb.pkl. "
BLCA,9.0,0.431372549,desert,NR,"Given a male patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was evaluated using mRNA TPM expression from a bladder biopsy and who has a tumor mutational burden of 9.0, how likely is this patient to respond to Atezolizumab therapy?","Given a male patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was evaluated using mRNA TPM expression from a bladder biopsy and who has a tumor mutational burden of 9.0, how likely is this patient to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2c9586-ar-2c95861.pkl. "
BLCA,,,inflamed,NR,"I have a male patient with bladder urothelial carcinoma who underwent a kidney biopsy for mRNA TPM expression analysis to evaluate the tumor immune microenvironment, but the tumor mutational burden result was not available (nan). Given these findings, how likely is the patient to respond to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma who underwent a kidney biopsy for mRNA TPM expression analysis to evaluate the tumor immune microenvironment, but the tumor mutational burden result was not available (nan). Given these findings, how likely is the patient to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2dc3f0-ar-2dc3f04.pkl. "
BLCA,14.0,2.705882353,excluded,NR,"For a male patient with bladder urothelial carcinoma who underwent a kidney biopsy for mRNA TPM expression analysis of the tumor immune microenvironment and has a tumor mutational burden of 14.0, how likely is he to respond to atezolizumab therapy?","For a male patient with bladder urothelial carcinoma who underwent a kidney biopsy for mRNA TPM expression analysis of the tumor immune microenvironment and has a tumor mutational burden of 14.0, how likely is he to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2e7aa8-ar-2e7aa8f.pkl. "
BLCA,18.0,1.764705882,,R,"In a patient with bladder urothelial carcinoma, the tumor mutational burden is 18.0 and mRNA TPM expression analysis from a bladder biopsy has been performed to assess the tumor immune microenvironment. Considering these findings, is the patient likely to benefit from treatment with atezolizumab?","In a patient with bladder urothelial carcinoma, the tumor mutational burden is 18.0 and mRNA TPM expression analysis from a bladder biopsy has been performed to assess the tumor immune microenvironment. Considering these findings, is the patient likely to benefit from treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2e9ac0-ar-2e9ac0b.pkl. "
BLCA,13.0,1.137254902,inflamed,R,"In a male patient with bladder urothelial carcinoma, the bladder biopsy showed mRNA TPM expression profiling of the tumor immune microenvironment and a tumor mutational burden of 13.0. Given these molecular findings, is the patient likely to respond favorably to treatment with atezolizumab?","In a male patient with bladder urothelial carcinoma, the bladder biopsy showed mRNA TPM expression profiling of the tumor immune microenvironment and a tumor mutational burden of 13.0. Given these molecular findings, is the patient likely to respond favorably to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2eb07d-ar-2eb07de.pkl. "
BLCA,8.0,0.450980392,excluded,NR,"I have a female patient with bladder urothelial carcinoma (BLCA) who underwent a bladder biopsy with mRNA TPM expression analysis to evaluate her tumor immune microenvironment. Given her tumor mutational burden of 8.0, would she be expected to respond favorably to atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma (BLCA) who underwent a bladder biopsy with mRNA TPM expression analysis to evaluate her tumor immune microenvironment. Given her tumor mutational burden of 8.0, would she be expected to respond favorably to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2f2289-ar-2f22893.pkl. "
BLCA,6.0,,excluded,R,"For a female patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated via mRNA TPM expression from a bladder biopsy and who has a tumor mutational burden of 6.0, do you anticipate a favorable response to atezolizumab therapy?","For a female patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated via mRNA TPM expression from a bladder biopsy and who has a tumor mutational burden of 6.0, do you anticipate a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/30b5c6-ar-30b5c6c.pkl. "
BLCA,,,excluded,NR,"I have a male patient with bladder urothelial carcinoma, and his bladder biopsy provided mRNA TPM expression data for assessing the tumor immune microenvironment. However, the tumor mutational burden (TMB) is reported as ""nan."" Considering these findings, is Atezolizumab likely to be an effective treatment option for this patient?","I have a male patient with bladder urothelial carcinoma, and his bladder biopsy provided mRNA TPM expression data for assessing the tumor immune microenvironment. However, the tumor mutational burden (TMB) is reported as ""nan."" Considering these findings, is Atezolizumab likely to be an effective treatment option for this patient?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/30cf07-ar-30cf07d.pkl. "
BLCA,23.0,4.235294118,inflamed,R,"I have a male patient with bladder urothelial carcinoma whose tumor mRNA expression was evaluated from a bladder biopsy to assess the immune microenvironment, and he has a tumor mutational burden of 23.0. Based on these findings, is he likely to respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose tumor mRNA expression was evaluated from a bladder biopsy to assess the immune microenvironment, and he has a tumor mutational burden of 23.0. Based on these findings, is he likely to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/31d917-ar-31d9176.pkl. "
BLCA,,0.705882353,,NR,"A female patient with bladder urothelial carcinoma underwent a lymph node biopsy with mRNA TPM expression analysis to evaluate the tumor immune microenvironment, and her tumor mutational burden is not available. Considering these factors, how likely is she to respond to treatment with atezolizumab?","A female patient with bladder urothelial carcinoma underwent a lymph node biopsy with mRNA TPM expression analysis to evaluate the tumor immune microenvironment, and her tumor mutational burden is not available. Considering these factors, how likely is she to respond to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/31f41d-ar-31f41dd.pkl. "
BLCA,2.0,,,NR,"A male patient with bladder urothelial carcinoma (BLCA) underwent a lymph node biopsy for mRNA TPM expression analysis to assess the tumor immune microenvironment, and his tumor mutational burden (TMB) is 2.0. Based on these findings, how likely is the patient to respond to Atezolizumab?","A male patient with bladder urothelial carcinoma (BLCA) underwent a lymph node biopsy for mRNA TPM expression analysis to assess the tumor immune microenvironment, and his tumor mutational burden (TMB) is 2.0. Based on these findings, how likely is the patient to respond to Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3330c0-ar-3330c03.pkl. "
BLCA,,,,NR,"I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was measured from a bladder biopsy for assessment of the tumor immune microenvironment. The tumor mutational burden is not available. Given these factors, what is the likelihood that the patient will respond favorably to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was measured from a bladder biopsy for assessment of the tumor immune microenvironment. The tumor mutational burden is not available. Given these factors, what is the likelihood that the patient will respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/34430e-ar-34430ef.pkl. "
BLCA,7.0,0.333333333,excluded,NR,"For my male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy has been evaluated to characterize the tumor immune microenvironment, and his tumor mutational burden is 7.0. Based on these findings, how likely is he to respond favorably to atezolizumab treatment?","For my male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy has been evaluated to characterize the tumor immune microenvironment, and his tumor mutational burden is 7.0. Based on these findings, how likely is he to respond favorably to atezolizumab treatment?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/36851b-ar-36851bc.pkl. "
BLCA,1.0,0.607843137,inflamed,NR,"I have a male patient with bladder urothelial carcinoma who underwent a biopsy with mRNA TPM expression analysis to evaluate the tumor immune microenvironment. With a tumor mutational burden of 1.0, would you expect him to respond favorably to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma who underwent a biopsy with mRNA TPM expression analysis to evaluate the tumor immune microenvironment. With a tumor mutational burden of 1.0, would you expect him to respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/36a922-ar-36a9225.pkl. "
BLCA,7.0,0.352941176,excluded,NR,"I have a patient with bladder urothelial carcinoma who underwent a ureter biopsy, with mRNA TPM expression analysis performed to evaluate the tumor immune microenvironment, and the tumor mutational burden is 7.0. Based on these findings, is it likely that the patient would respond to Atezolizumab therapy?","I have a patient with bladder urothelial carcinoma who underwent a ureter biopsy, with mRNA TPM expression analysis performed to evaluate the tumor immune microenvironment, and the tumor mutational burden is 7.0. Based on these findings, is it likely that the patient would respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/36d873-ar-36d8739.pkl. "
BLCA,5.0,,excluded,NR,"For a male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 5.0 and mRNA TPM expression data from a bladder biopsy assessing the tumor immune microenvironment, what is the likelihood of a positive response to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 5.0 and mRNA TPM expression data from a bladder biopsy assessing the tumor immune microenvironment, what is the likelihood of a positive response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3894ac-ar-3894ac3.pkl. "
BLCA,6.0,,excluded,NR,"In a male patient with bladder urothelial carcinoma, how would a tumor mutational burden of 6.0 and mRNA TPM expression data from a bladder biopsy inform the likelihood of response to atezolizumab?","In a male patient with bladder urothelial carcinoma, how would a tumor mutational burden of 6.0 and mRNA TPM expression data from a bladder biopsy inform the likelihood of response to atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/39eb94-ar-39eb94f.pkl. "
BLCA,,,,NR,"I have a male patient with bladder urothelial carcinoma who underwent mRNA TPM expression analysis from a lung biopsy to evaluate the tumor immune microenvironment, although his tumor mutational burden is not available. Given these factors, would you expect him to respond to Atezolizumab?","I have a male patient with bladder urothelial carcinoma who underwent mRNA TPM expression analysis from a lung biopsy to evaluate the tumor immune microenvironment, although his tumor mutational burden is not available. Given these factors, would you expect him to respond to Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3a1c96-ar-3a1c963.pkl. "
BLCA,2.0,0.176470588,excluded,NR,"For a male patient with bladder urothelial carcinoma (BLCA) whose lymph node biopsy revealed mRNA TPM expression profiling of the tumor immune microenvironment and a tumor mutational burden (TMB) of 2.0, how likely is it that treatment with Atezolizumab would be effective?","For a male patient with bladder urothelial carcinoma (BLCA) whose lymph node biopsy revealed mRNA TPM expression profiling of the tumor immune microenvironment and a tumor mutational burden (TMB) of 2.0, how likely is it that treatment with Atezolizumab would be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3b1066-ar-3b1066e.pkl. "
BLCA,44.0,5.823529412,inflamed,R,"I have a male patient with bladder urothelial carcinoma who underwent a bladder biopsy, with mRNA TPM expression measured to assess the tumor immune microenvironment and a tumor mutational burden of 44.0. Based on these results, what is the likelihood that the patient will respond to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma who underwent a bladder biopsy, with mRNA TPM expression measured to assess the tumor immune microenvironment and a tumor mutational burden of 44.0. Based on these results, what is the likelihood that the patient will respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3b15b4-ar-3b15b4c.pkl. "
BLCA,15.0,2.235294118,excluded,NR,"I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression has been assessed via a kidney biopsy to evaluate the tumor immune microenvironment, and his tumor mutational burden is 15.0. Given this information, is he likely to respond favorably to atezolizumab treatment?","I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression has been assessed via a kidney biopsy to evaluate the tumor immune microenvironment, and his tumor mutational burden is 15.0. Given this information, is he likely to respond favorably to atezolizumab treatment?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3cb94b-ar-3cb94b0.pkl. "
BLCA,17.0,1.411764706,excluded,R,"For a male patient with bladder urothelial carcinoma, whose lymph node biopsy showed mRNA TPM expression indicative of the tumor immune microenvironment and a tumor mutational burden of 17.0, would you anticipate a favorable response to atezolizumab therapy?","For a male patient with bladder urothelial carcinoma, whose lymph node biopsy showed mRNA TPM expression indicative of the tumor immune microenvironment and a tumor mutational burden of 17.0, would you anticipate a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3e04eb-ar-3e04eb9.pkl. "
BLCA,11.0,1.215686275,desert,NR,"I have a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression from a kidney biopsy, and his tumor mutational burden is 11.0. Considering these results, how likely is he to respond to treatment with atezolizumab?","I have a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression from a kidney biopsy, and his tumor mutational burden is 11.0. Considering these results, how likely is he to respond to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3e8baf-ar-3e8baff.pkl. "
BLCA,,,desert,NR,"For a male patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment was evaluated through mRNA TPM expression from a bladder biopsy and who has an indeterminate tumor mutational burden (TMB reported as “nan”), would you anticipate a favorable response to treatment with atezolizumab?","For a male patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment was evaluated through mRNA TPM expression from a bladder biopsy and who has an indeterminate tumor mutational burden (TMB reported as “nan”), would you anticipate a favorable response to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3ee5dc-ar-3ee5dcd.pkl. "
BLCA,,0.431372549,excluded,NR,"I have a male patient diagnosed with bladder urothelial carcinoma. A bladder biopsy was performed, and mRNA TPM expression was measured to evaluate the tumor immune microenvironment. Although the tumor mutational burden (TMB) data is unavailable (not a number), I am considering treatment with atezolizumab. Given these clinical and molecular parameters, could you provide insight into the likelihood of a favorable response to atezolizumab therapy?","I have a male patient diagnosed with bladder urothelial carcinoma. A bladder biopsy was performed, and mRNA TPM expression was measured to evaluate the tumor immune microenvironment. Although the tumor mutational burden (TMB) data is unavailable (not a number), I am considering treatment with atezolizumab. Given these clinical and molecular parameters, could you provide insight into the likelihood of a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/415f36-ar-415f36a.pkl. "
BLCA,12.0,0.392156863,desert,NR,"I have a male patient with bladder urothelial carcinoma who underwent a bladder biopsy for mRNA TPM expression analysis to assess the tumor immune microenvironment, and his tumor mutational burden is 12.0. Based on these findings, do you think he is likely to respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma who underwent a bladder biopsy for mRNA TPM expression analysis to assess the tumor immune microenvironment, and his tumor mutational burden is 12.0. Based on these findings, do you think he is likely to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4305ab-ar-4305ab9.pkl. "
BLCA,6.0,0.921568627,excluded,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression was evaluated from a bladder biopsy to characterize the tumor immune microenvironment, and he has a tumor mutational burden of 6.0. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression was evaluated from a bladder biopsy to characterize the tumor immune microenvironment, and he has a tumor mutational burden of 6.0. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4501e4-ar-4501e41.pkl. "
BLCA,5.0,1.392156863,inflamed,NR,"I have a male patient with bladder urothelial carcinoma (BLCA) whose tumor sample from a bladder biopsy was analyzed for mRNA TPM expression to evaluate the immune microenvironment. With a tumor mutational burden (TMB) of 5.0, is he likely to respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma (BLCA) whose tumor sample from a bladder biopsy was analyzed for mRNA TPM expression to evaluate the immune microenvironment. With a tumor mutational burden (TMB) of 5.0, is he likely to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/45c8e6-ar-45c8e64.pkl. "
BLCA,8.0,,desert,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a nanobiopsy was assessed to evaluate the tumor immune microenvironment, and the tumor mutational burden is 8.0 mutations per megabase. Given these findings, how likely is it that the patient will respond to treatment with atezolizumab?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a nanobiopsy was assessed to evaluate the tumor immune microenvironment, and the tumor mutational burden is 8.0 mutations per megabase. Given these findings, how likely is it that the patient will respond to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/468a9e-ar-468a9e1.pkl. "
BLCA,8.0,0.803921569,inflamed,NR,"For a male patient with bladder urothelial carcinoma who has undergone mRNA TPM expression analysis to evaluate the tumor immune microenvironment and presents with a tumor mutational burden of 8.0, would you expect a favorable response to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma who has undergone mRNA TPM expression analysis to evaluate the tumor immune microenvironment and presents with a tumor mutational burden of 8.0, would you expect a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/47fc46-ar-47fc46c.pkl. "
BLCA,0.0,0.607843137,excluded,NR,"For our male bladder cancer patient with urothelial carcinoma, mRNA transcript levels were measured from a bladder biopsy to assess the tumor immune microenvironment, and the tumor mutational burden is 0.0. Given these findings, what is the likelihood of a favorable response to atezolizumab therapy?","For our male bladder cancer patient with urothelial carcinoma, mRNA transcript levels were measured from a bladder biopsy to assess the tumor immune microenvironment, and the tumor mutational burden is 0.0. Given these findings, what is the likelihood of a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/49d487-ar-49d4875.pkl. "
BLCA,5.0,1.450980392,excluded,NR,"In a male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 5.0 and whose mRNA TPM expression was measured from a kidney biopsy to evaluate the tumor immune microenvironment, how likely is he to respond to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 5.0 and whose mRNA TPM expression was measured from a kidney biopsy to evaluate the tumor immune microenvironment, how likely is he to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/49f9b2-ar-49f9b2e.pkl. "
BLCA,6.0,,desert,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a kidney biopsy was used to characterize the tumor immune microenvironment, and the tumor mutational burden is 6.0. Given these findings, how likely is it that the patient will respond to Atezolizumab?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a kidney biopsy was used to characterize the tumor immune microenvironment, and the tumor mutational burden is 6.0. Given these findings, how likely is it that the patient will respond to Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4b0175-ar-4b0175e.pkl. "
BLCA,,,excluded,NR,"I have a female patient with bladder urothelial carcinoma who underwent a kidney biopsy for mRNA TPM analysis of the tumor immune microenvironment, and her tumor mutational burden is reported as nan. Based on these findings, how likely is she to respond to treatment with atezolizumab?","I have a female patient with bladder urothelial carcinoma who underwent a kidney biopsy for mRNA TPM analysis of the tumor immune microenvironment, and her tumor mutational burden is reported as nan. Based on these findings, how likely is she to respond to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4b7ea0-ar-4b7ea01.pkl. "
BLCA,59.0,11.68627451,excluded,R,"In a male patient with bladder urothelial carcinoma, the tumor mutational burden is 59.0, and mRNA TPM expression was analyzed from a ureter biopsy to evaluate the tumor immune microenvironment. Based on these findings, would you anticipate a favorable response to Atezolizumab?","In a male patient with bladder urothelial carcinoma, the tumor mutational burden is 59.0, and mRNA TPM expression was analyzed from a ureter biopsy to evaluate the tumor immune microenvironment. Based on these findings, would you anticipate a favorable response to Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4caabd-ar-4caabd6.pkl. "
BLCA,13.0,0.31372549,desert,NR,"I have a male patient with bladder urothelial carcinoma (BLCA) whose tumor tissue, obtained via a kidney biopsy, was analyzed for mRNA TPM expression to assess the tumor immune microenvironment. The patient's tumor mutational burden (TMB) is 13.0 mutations/Mb. Based on these findings, what is the likelihood of a favorable response to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma (BLCA) whose tumor tissue, obtained via a kidney biopsy, was analyzed for mRNA TPM expression to assess the tumor immune microenvironment. The patient's tumor mutational burden (TMB) is 13.0 mutations/Mb. Based on these findings, what is the likelihood of a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/523468-ar-5234688.pkl. "
BLCA,12.0,0.745098039,excluded,NR,"Considering the patient's bladder urothelial carcinoma, a tumor mutational burden of 12.0, and the mRNA TPM expression profile obtained from a ureter biopsy to assess the tumor immune microenvironment, is she likely to respond to Atezolizumab therapy?","Considering the patient's bladder urothelial carcinoma, a tumor mutational burden of 12.0, and the mRNA TPM expression profile obtained from a ureter biopsy to assess the tumor immune microenvironment, is she likely to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/52500c-ar-52500ca.pkl. "
BLCA,4.0,0.254901961,,NR,"For a patient with bladder urothelial carcinoma who has a tumor mutational burden of 4.0 and available mRNA TPM expression data from a lymph node biopsy assessing the tumor immune microenvironment, can we anticipate a favorable response to atezolizumab therapy?","For a patient with bladder urothelial carcinoma who has a tumor mutational burden of 4.0 and available mRNA TPM expression data from a lymph node biopsy assessing the tumor immune microenvironment, can we anticipate a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/52e3fa-ar-52e3fa3.pkl. "
BLCA,11.0,1.823529412,desert,R,"In evaluating a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 11.0 and mRNA TPM expression data from a bladder biopsy characterizing the tumor immune microenvironment, what is the likelihood of a beneficial clinical response to atezolizumab therapy?","In evaluating a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 11.0 and mRNA TPM expression data from a bladder biopsy characterizing the tumor immune microenvironment, what is the likelihood of a beneficial clinical response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/548551-ar-548551e.pkl. "
BLCA,5.0,,desert,NR,"In a male patient with bladder urothelial carcinoma who underwent mRNA TPM expression profiling of a bladder biopsy to assess the tumor immune microenvironment and has a tumor mutational burden of 5.0, is treatment with atezolizumab likely to be effective?","In a male patient with bladder urothelial carcinoma who underwent mRNA TPM expression profiling of a bladder biopsy to assess the tumor immune microenvironment and has a tumor mutational burden of 5.0, is treatment with atezolizumab likely to be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/54e58f-ar-54e58f1.pkl. "
BLCA,,,,NR,"I have a female patient with bladder urothelial carcinoma. Her mRNA TPM expression was measured from a kidney biopsy to evaluate the tumor immune microenvironment, and her tumor mutational burden is currently unknown. Considering these factors, what is the likelihood that she will respond to treatment with Atezolizumab?","I have a female patient with bladder urothelial carcinoma. Her mRNA TPM expression was measured from a kidney biopsy to evaluate the tumor immune microenvironment, and her tumor mutational burden is currently unknown. Considering these factors, what is the likelihood that she will respond to treatment with Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/553c3c-ar-553c3c3.pkl. "
BLCA,5.0,,excluded,NR,"I have a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression from a ureter biopsy, and his tumor mutational burden is 5.0. Given these findings, would you consider him a likely candidate for a favorable response to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression from a ureter biopsy, and his tumor mutational burden is 5.0. Given these findings, would you consider him a likely candidate for a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/557dde-ar-557dde1.pkl. "
BLCA,19.0,0.647058824,inflamed,R,"In a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 19.0 and mRNA TPM expression data from a separate biopsy assessing the tumor immune microenvironment, would these factors predict a favorable response to atezolizumab therapy?","In a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 19.0 and mRNA TPM expression data from a separate biopsy assessing the tumor immune microenvironment, would these factors predict a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/560f23-ar-560f23d.pkl. "
BLCA,,0.607843137,,NR,"I have a male patient with bladder urothelial carcinoma, and we've measured mRNA TPM expression from a bladder biopsy to evaluate the tumor immune microenvironment. The tumor mutational burden data is not available. Based on these findings, how predictive is this profile of a favorable response to Atezolizumab treatment?","I have a male patient with bladder urothelial carcinoma, and we've measured mRNA TPM expression from a bladder biopsy to evaluate the tumor immune microenvironment. The tumor mutational burden data is not available. Based on these findings, how predictive is this profile of a favorable response to Atezolizumab treatment?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/563d62-ar-563d623.pkl. "
BLCA,,,,NR,"I have a female patient with bladder urothelial carcinoma whose tumor immune microenvironment was characterized via mRNA TPM expression profiling from a bladder biopsy. However, her tumor mutational burden was not quantifiable. Given these findings, how likely is she to benefit from treatment with Atezolizumab?","I have a female patient with bladder urothelial carcinoma whose tumor immune microenvironment was characterized via mRNA TPM expression profiling from a bladder biopsy. However, her tumor mutational burden was not quantifiable. Given these findings, how likely is she to benefit from treatment with Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/568ce1-ar-568ce16.pkl. "
BLCA,33.0,5.509803922,excluded,R,"For a male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was assessed via mRNA TPM expression from a kidney biopsy and who has a tumor mutational burden of 33.0, would you anticipate that atezolizumab therapy is likely to be effective?","For a male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was assessed via mRNA TPM expression from a kidney biopsy and who has a tumor mutational burden of 33.0, would you anticipate that atezolizumab therapy is likely to be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/572f19-ar-572f197.pkl. "
BLCA,32.0,,excluded,R,"I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was assessed from a previous biopsy to evaluate the tumor immune microenvironment. With a tumor mutational burden of 32.0, would treatment with Atezolizumab be likely to yield a positive response in this case?","I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was assessed from a previous biopsy to evaluate the tumor immune microenvironment. With a tumor mutational burden of 32.0, would treatment with Atezolizumab be likely to yield a positive response in this case?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5767dd-ar-5767dd7.pkl. "
BLCA,2.0,0.333333333,desert,R,"I have a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression profiling from a bladder biopsy. Given that his tumor mutational burden is 2.0, how likely is he to respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression profiling from a bladder biopsy. Given that his tumor mutational burden is 2.0, how likely is he to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/58e783-ar-58e7832.pkl. "
BLCA,14.0,,excluded,NR,"Given a patient with bladder urothelial carcinoma who has a tumor mutational burden of 14.0 and mRNA TPM expression data from a bladder biopsy used to evaluate the tumor immune microenvironment, how likely is it that the patient will respond to Atezolizumab therapy?","Given a patient with bladder urothelial carcinoma who has a tumor mutational burden of 14.0 and mRNA TPM expression data from a bladder biopsy used to evaluate the tumor immune microenvironment, how likely is it that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/59f392-ar-59f3928.pkl. "
BLCA,,,,NR,"I have a male patient with bladder urothelial carcinoma (BLCA) for whom mRNA TPM expression data were obtained via nanobiopsy to evaluate the tumor immune microenvironment. With a tumor mutational burden of nan, how likely is this patient to respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma (BLCA) for whom mRNA TPM expression data were obtained via nanobiopsy to evaluate the tumor immune microenvironment. With a tumor mutational burden of nan, how likely is this patient to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/59fda9-ar-59fda90.pkl. "
BLCA,9.0,1.333333333,desert,NR,"In a male patient with bladder urothelial carcinoma, where mRNA TPM expression profiling from a bladder biopsy has been used to evaluate the tumor immune microenvironment and the tumor mutational burden is 9.0, how likely is it that he will respond to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, where mRNA TPM expression profiling from a bladder biopsy has been used to evaluate the tumor immune microenvironment and the tumor mutational burden is 9.0, how likely is it that he will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5a2347-ar-5a2347c.pkl. "
BLCA,12.0,,,NR,"In a female patient with bladder urothelial carcinoma (BLCA), mRNA TPM expression was measured from a ureter biopsy to characterize the tumor immune microenvironment, and a tumor mutational burden (TMB) of 12.0 was identified. Based on these findings, is the patient likely to have a favorable response to Atezolizumab therapy?","In a female patient with bladder urothelial carcinoma (BLCA), mRNA TPM expression was measured from a ureter biopsy to characterize the tumor immune microenvironment, and a tumor mutational burden (TMB) of 12.0 was identified. Based on these findings, is the patient likely to have a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5b57e4-ar-5b57e47.pkl. "
BLCA,,,excluded,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression analysis from a bladder biopsy has been used to evaluate the tumor immune microenvironment, but the tumor mutational burden is unavailable. Based on this information, how likely is it that the patient will respond favorably to Atezolizumab?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression analysis from a bladder biopsy has been used to evaluate the tumor immune microenvironment, but the tumor mutational burden is unavailable. Based on this information, how likely is it that the patient will respond favorably to Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5c139c-ar-5c139c5.pkl. "
BLCA,11.0,0.411764706,desert,NR,"For a male patient with bladder urothelial carcinoma, whose bladder biopsy revealed mRNA expression levels (TPM) indicative of the tumor immune microenvironment and a tumor mutational burden of 11.0 mutations per megabase, is immunotherapy with Atezolizumab likely to be effective?","For a male patient with bladder urothelial carcinoma, whose bladder biopsy revealed mRNA expression levels (TPM) indicative of the tumor immune microenvironment and a tumor mutational burden of 11.0 mutations per megabase, is immunotherapy with Atezolizumab likely to be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5cc2d9-ar-5cc2d90.pkl. "
BLCA,10.0,1.215686275,,NR,"We have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was assessed via liver biopsy to evaluate the tumor immune microenvironment, and his tumor mutational burden (TMB) is 10.0. Based on these clinical and molecular findings, is he likely to respond to Atezolizumab therapy?","We have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was assessed via liver biopsy to evaluate the tumor immune microenvironment, and his tumor mutational burden (TMB) is 10.0. Based on these clinical and molecular findings, is he likely to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5cfa16-ar-5cfa169.pkl. "
BLCA,12.0,,,NR,"I have a male patient with bladder urothelial carcinoma whose tumor biopsy revealed mRNA TPM expression data used to assess the immune microenvironment, and his tumor mutational burden is 12.0. Based on these findings, would you expect him to respond favorably to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose tumor biopsy revealed mRNA TPM expression data used to assess the immune microenvironment, and his tumor mutational burden is 12.0. Based on these findings, would you expect him to respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5d1dfd-ar-5d1dfd5.pkl. "
BLCA,13.0,1.411764706,desert,NR,"A female patient with bladder urothelial carcinoma has undergone mRNA TPM expression profiling from a bladder biopsy, and her tumor mutational burden is 13.0. Given these findings, is she likely to benefit from treatment with Atezolizumab?","A female patient with bladder urothelial carcinoma has undergone mRNA TPM expression profiling from a bladder biopsy, and her tumor mutational burden is 13.0. Given these findings, is she likely to benefit from treatment with Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5d989c-ar-5d989c8.pkl. "
BLCA,6.0,0.823529412,excluded,NR,"I have a male patient diagnosed with bladder urothelial carcinoma. mRNA TPM expression from a kidney biopsy was used to evaluate the tumor immune microenvironment, and the tumor mutational burden is 6.0. Given these findings, what is the likelihood that he will respond to atezolizumab therapy?","I have a male patient diagnosed with bladder urothelial carcinoma. mRNA TPM expression from a kidney biopsy was used to evaluate the tumor immune microenvironment, and the tumor mutational burden is 6.0. Given these findings, what is the likelihood that he will respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5e3bae-ar-5e3bae0.pkl. "
BLCA,21.0,3.823529412,inflamed,NR,"Given a male patient with bladder urothelial carcinoma whose tumor mutational burden is 21.0 and whose tumor immune microenvironment was evaluated via mRNA TPM expression from a ureter biopsy, how likely is the patient to respond to Atezolizumab therapy?","Given a male patient with bladder urothelial carcinoma whose tumor mutational burden is 21.0 and whose tumor immune microenvironment was evaluated via mRNA TPM expression from a ureter biopsy, how likely is the patient to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5fe7a8-ar-5fe7a81.pkl. "
BLCA,14.0,,inflamed,R,"A patient with bladder urothelial carcinoma has undergone a bladder biopsy to measure mRNA TPM expression for characterization of the tumor immune microenvironment and exhibits a tumor mutational burden of 14.0. Based on these findings, how likely is the patient to respond to atezolizumab therapy?","A patient with bladder urothelial carcinoma has undergone a bladder biopsy to measure mRNA TPM expression for characterization of the tumor immune microenvironment and exhibits a tumor mutational burden of 14.0. Based on these findings, how likely is the patient to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6083aa-ar-6083aac.pkl. "
BLCA,9.0,1.803921569,desert,R,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy was assessed to evaluate the tumor immune microenvironment, and the tumor mutational burden is 9.0. Given these biomarkers, would you expect a favorable response to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy was assessed to evaluate the tumor immune microenvironment, and the tumor mutational burden is 9.0. Given these biomarkers, would you expect a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6157c8-ar-6157c8f.pkl. "
BLCA,27.0,5.882352941,inflamed,NR,"In a patient with bladder urothelial carcinoma who has undergone mRNA TPM expression analysis of a bladder biopsy to evaluate the tumor immune microenvironment, and who exhibits a tumor mutational burden of 27.0, how might we predict the likelihood of a favorable response to atezolizumab therapy?","In a patient with bladder urothelial carcinoma who has undergone mRNA TPM expression analysis of a bladder biopsy to evaluate the tumor immune microenvironment, and who exhibits a tumor mutational burden of 27.0, how might we predict the likelihood of a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/61b9d4-ar-61b9d4d.pkl. "
BLCA,,,desert,NR,"For a female patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression from a lymph node biopsy and with an undetermined tumor mutational burden, is treatment with Atezolizumab likely to be effective?","For a female patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression from a lymph node biopsy and with an undetermined tumor mutational burden, is treatment with Atezolizumab likely to be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/61baf9-ar-61baf91.pkl. "
BLCA,5.0,0.784313725,,NR,"For a female patient with bladder urothelial carcinoma evaluated by mRNA TPM expression from a kidney biopsy, and with a tumor mutational burden of 5.0, how likely is she to respond to atezolizumab therapy?","For a female patient with bladder urothelial carcinoma evaluated by mRNA TPM expression from a kidney biopsy, and with a tumor mutational burden of 5.0, how likely is she to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/62fb13-ar-62fb138.pkl. "
BLCA,,0.156862745,,NR,"I have a patient with bladder urothelial carcinoma in whom mRNA TPM expression was obtained from a bladder biopsy to evaluate the tumor immune microenvironment. Given that the tumor mutational burden is not available, would this patient be a likely candidate for Atezolizumab therapy?","I have a patient with bladder urothelial carcinoma in whom mRNA TPM expression was obtained from a bladder biopsy to evaluate the tumor immune microenvironment. Given that the tumor mutational burden is not available, would this patient be a likely candidate for Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/63405b-ar-63405b0.pkl. "
BLCA,14.0,0.980392157,desert,NR,"Given a male patient with bladder urothelial carcinoma whose tumor mRNA TPM expression was evaluated via bladder biopsy, and with a tumor mutational burden of 14.0, is treatment with atezolizumab likely to be effective?","Given a male patient with bladder urothelial carcinoma whose tumor mRNA TPM expression was evaluated via bladder biopsy, and with a tumor mutational burden of 14.0, is treatment with atezolizumab likely to be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/63b218-ar-63b2189.pkl. "
BLCA,4.0,0.294117647,excluded,NR,"In a male patient with bladder urothelial carcinoma, mRNA expression levels (TPM) from a bladder biopsy were analyzed to assess the tumor immune microenvironment, and the tumor mutational burden is 4.0. Based on these findings, is treatment with atezolizumab likely to be effective?","In a male patient with bladder urothelial carcinoma, mRNA expression levels (TPM) from a bladder biopsy were analyzed to assess the tumor immune microenvironment, and the tumor mutational burden is 4.0. Based on these findings, is treatment with atezolizumab likely to be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/65afda-ar-65afda2.pkl. "
BLCA,5.0,0.490196078,inflamed,NR,"For a male patient with bladder urothelial carcinoma, whose tumor mRNA TPM expression was evaluated from a bladder biopsy to characterize the tumor immune microenvironment, and with a tumor mutational burden of 5.0 mutations per megabase, what is the likelihood of a favorable response to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma, whose tumor mRNA TPM expression was evaluated from a bladder biopsy to characterize the tumor immune microenvironment, and with a tumor mutational burden of 5.0 mutations per megabase, what is the likelihood of a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6662f5-ar-6662f51.pkl. "
BLCA,15.0,2.68627451,excluded,R,"In a female patient with bladder urothelial carcinoma who has undergone a bladder biopsy for mRNA TPM expression profiling to assess the tumor immune microenvironment, and with a tumor mutational burden of 15.0, is it likely that Atezolizumab therapy will be effective?","In a female patient with bladder urothelial carcinoma who has undergone a bladder biopsy for mRNA TPM expression profiling to assess the tumor immune microenvironment, and with a tumor mutational burden of 15.0, is it likely that Atezolizumab therapy will be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/670649-ar-670649e.pkl. "
BLCA,13.0,1.254901961,desert,NR,"I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was measured from a bladder biopsy to evaluate the tumor immune microenvironment. With a tumor mutational burden of 13.0, how likely is this patient to respond to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was measured from a bladder biopsy to evaluate the tumor immune microenvironment. With a tumor mutational burden of 13.0, how likely is this patient to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/675a12-ar-675a12a.pkl. "
BLCA,14.0,2.549019608,inflamed,NR,"I have a female patient with bladder urothelial carcinoma (BLCA) whose mRNA TPM expression was measured from a bladder biopsy to assess the tumor immune microenvironment. With a tumor mutational burden of 14.0, do you think she is likely to respond to atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma (BLCA) whose mRNA TPM expression was measured from a bladder biopsy to assess the tumor immune microenvironment. With a tumor mutational burden of 14.0, do you think she is likely to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6780ed-ar-6780ed4.pkl. "
BLCA,17.0,1.117647059,desert,NR,"For a male patient with bladder urothelial carcinoma who has undergone mRNA TPM profiling from a bladder biopsy to evaluate the tumor immune microenvironment, and who has a tumor mutational burden of 17 mutations per megabase, how likely is he to respond to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma who has undergone mRNA TPM profiling from a bladder biopsy to evaluate the tumor immune microenvironment, and who has a tumor mutational burden of 17 mutations per megabase, how likely is he to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6792d6-ar-6792d6e.pkl. "
BLCA,7.0,1.862745098,excluded,R,"In a patient with bladder urothelial carcinoma demonstrating a tumor mutational burden of 7.0 and mRNA TPM expression profiling from a bladder biopsy, how likely is a favorable response to Atezolizumab therapy based on the tumor immune microenvironment?","In a patient with bladder urothelial carcinoma demonstrating a tumor mutational burden of 7.0 and mRNA TPM expression profiling from a bladder biopsy, how likely is a favorable response to Atezolizumab therapy based on the tumor immune microenvironment?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/681e4b-ar-681e4bf.pkl. "
BLCA,5.0,1.176470588,,NR,"I have a male patient with bladder urothelial carcinoma whose tumor mRNA expression has been quantified (in TPM) from a biopsy to assess the immune microenvironment. The tumor exhibits a mutational burden of 5.0 mutations per megabase. Given these factors, how likely is the patient to respond to Atezolizumab treatment?","I have a male patient with bladder urothelial carcinoma whose tumor mRNA expression has been quantified (in TPM) from a biopsy to assess the immune microenvironment. The tumor exhibits a mutational burden of 5.0 mutations per megabase. Given these factors, how likely is the patient to respond to Atezolizumab treatment?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6964a6-ar-6964a6d.pkl. "
BLCA,20.0,1.039215686,desert,R,"Considering a male patient with bladder urothelial carcinoma (BLCA), whose tumor mRNA TPM expression was assessed via a lung biopsy revealing a tumor mutational burden (TMB) of 20.0, would these biomarker findings suggest a favorable response to Atezolizumab therapy?","Considering a male patient with bladder urothelial carcinoma (BLCA), whose tumor mRNA TPM expression was assessed via a lung biopsy revealing a tumor mutational burden (TMB) of 20.0, would these biomarker findings suggest a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6cb230-ar-6cb230f.pkl. "
BLCA,3.0,0.960784314,inflamed,NR,"A male patient with bladder urothelial carcinoma underwent a bladder biopsy for mRNA TPM expression analysis of the tumor immune microenvironment, and his tumor mutational burden is 3.0. Given these findings, what is the likelihood that he would respond favorably to atezolizumab therapy?","A male patient with bladder urothelial carcinoma underwent a bladder biopsy for mRNA TPM expression analysis of the tumor immune microenvironment, and his tumor mutational burden is 3.0. Given these findings, what is the likelihood that he would respond favorably to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6cbc10-ar-6cbc10a.pkl. "
BLCA,,,excluded,NR,"I am evaluating a male patient with bladder urothelial carcinoma who underwent lymph node biopsy with mRNA TPM expression analysis to assess the tumor immune microenvironment. Given that his tumor mutational burden data is unavailable, how might these factors influence his potential response to Atezolizumab therapy?","I am evaluating a male patient with bladder urothelial carcinoma who underwent lymph node biopsy with mRNA TPM expression analysis to assess the tumor immune microenvironment. Given that his tumor mutational burden data is unavailable, how might these factors influence his potential response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6d2ae0-ar-6d2ae0c.pkl. "
BLCA,,3.568627451,,NR,"I have a male patient with bladder urothelial carcinoma whose tumor microenvironment has been evaluated via mRNA TPM expression analysis from a bladder biopsy. Although the tumor mutational burden data is not available, I am considering treatment with atezolizumab. Based on these parameters, what is the anticipated likelihood of a response to atezolizumab treatment?","I have a male patient with bladder urothelial carcinoma whose tumor microenvironment has been evaluated via mRNA TPM expression analysis from a bladder biopsy. Although the tumor mutational burden data is not available, I am considering treatment with atezolizumab. Based on these parameters, what is the anticipated likelihood of a response to atezolizumab treatment?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6dd7ad-ar-6dd7ad1.pkl. "
BLCA,8.0,2.078431373,,R,"I have a female patient with bladder urothelial carcinoma whose mRNA TPM expression was assessed via nano-biopsy to evaluate the tumor immune microenvironment, and her tumor mutational burden is 8.0. Based on these factors, is she likely to respond to Atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma whose mRNA TPM expression was assessed via nano-biopsy to evaluate the tumor immune microenvironment, and her tumor mutational burden is 8.0. Based on these factors, is she likely to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6f2a10-ar-6f2a102.pkl. "
BLCA,6.0,1.039215686,excluded,R,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression was assessed from a kidney biopsy to evaluate the tumor immune microenvironment, and his tumor mutational burden is reported to be 6.0. Given these findings, what is the expected likelihood of a favorable response to atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression was assessed from a kidney biopsy to evaluate the tumor immune microenvironment, and his tumor mutational burden is reported to be 6.0. Given these findings, what is the expected likelihood of a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6ff654-ar-6ff654a.pkl. "
BLCA,17.0,2.176470588,,NR,"In a male patient with bladder urothelial carcinoma whose bladder biopsy shows specific mRNA TPM expression profiling of the tumor immune microenvironment and a tumor mutational burden of 17.0, how likely is the patient to respond to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma whose bladder biopsy shows specific mRNA TPM expression profiling of the tumor immune microenvironment and a tumor mutational burden of 17.0, how likely is the patient to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7114d9-ar-7114d99.pkl. "
BLCA,6.0,1.568627451,,NR,"In a patient with bladder urothelial carcinoma whose tumor profiling includes mRNA TPM expression from a kidney biopsy to assess the immune microenvironment and a tumor mutational burden of 6.0, how likely is it that they will benefit from Atezolizumab therapy?","In a patient with bladder urothelial carcinoma whose tumor profiling includes mRNA TPM expression from a kidney biopsy to assess the immune microenvironment and a tumor mutational burden of 6.0, how likely is it that they will benefit from Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/716f54-ar-716f54e.pkl. "
BLCA,1.0,0.333333333,,R,"For a patient with bladder urothelial carcinoma who has undergone lymph node biopsy with mRNA TPM expression analysis of the tumor immune microenvironment and exhibits a tumor mutational burden of 1.0, is Atezolizumab likely to be an effective treatment option?","For a patient with bladder urothelial carcinoma who has undergone lymph node biopsy with mRNA TPM expression analysis of the tumor immune microenvironment and exhibits a tumor mutational burden of 1.0, is Atezolizumab likely to be an effective treatment option?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/727c0e-ar-727c0e9.pkl. "
BLCA,,,excluded,R,"For a patient with bladder urothelial carcinoma whose tumor immune microenvironment was assessed using mRNA TPM expression from a kidney biopsy and reported a tumor mutational burden of ""nan,"" is there evidence to suggest that Atezolizumab would be an effective treatment option?","For a patient with bladder urothelial carcinoma whose tumor immune microenvironment was assessed using mRNA TPM expression from a kidney biopsy and reported a tumor mutational burden of ""nan,"" is there evidence to suggest that Atezolizumab would be an effective treatment option?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/73663e-ar-73663ee.pkl. "
BLCA,7.0,0.274509804,excluded,NR,"In a female patient with bladder urothelial carcinoma, mRNA TPM expression has been assessed from a kidney biopsy to evaluate the tumor immune microenvironment, and her tumor mutational burden is 7.0. Considering Atezolizumab therapy, do these factors suggest she is likely to respond to treatment?","In a female patient with bladder urothelial carcinoma, mRNA TPM expression has been assessed from a kidney biopsy to evaluate the tumor immune microenvironment, and her tumor mutational burden is 7.0. Considering Atezolizumab therapy, do these factors suggest she is likely to respond to treatment?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/75142f-ar-75142fc.pkl. "
BLCA,21.0,2.392156863,inflamed,NR,"In a patient with bladder urothelial carcinoma whose bladder biopsy revealed mRNA TPM expression data for evaluating the tumor immune microenvironment and a tumor mutational burden of 21.0, would these factors suggest a favorable response to atezolizumab therapy?","In a patient with bladder urothelial carcinoma whose bladder biopsy revealed mRNA TPM expression data for evaluating the tumor immune microenvironment and a tumor mutational burden of 21.0, would these factors suggest a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7538ad-ar-7538ad9.pkl. "
BLCA,7.0,,excluded,NR,"I have a male patient with bladder urothelial carcinoma whose tumor mRNA TPM expression was assessed via a ureter biopsy to evaluate the tumor immune microenvironment. The tumor’s mutation burden is 7.0. Given these factors, could this patient potentially benefit from treatment with Atezolizumab?","I have a male patient with bladder urothelial carcinoma whose tumor mRNA TPM expression was assessed via a ureter biopsy to evaluate the tumor immune microenvironment. The tumor’s mutation burden is 7.0. Given these factors, could this patient potentially benefit from treatment with Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/753d4b-ar-753d4bb.pkl. "
BLCA,6.0,0.333333333,inflamed,NR,"In a patient with bladder urothelial carcinoma who has a tumor mutational burden of 6.0 and mRNA TPM expression data obtained from a lung biopsy to evaluate the immune microenvironment, is there evidence to suggest that Atezolizumab would be an effective treatment option?","In a patient with bladder urothelial carcinoma who has a tumor mutational burden of 6.0 and mRNA TPM expression data obtained from a lung biopsy to evaluate the immune microenvironment, is there evidence to suggest that Atezolizumab would be an effective treatment option?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/75f12d-ar-75f12d1.pkl. "
BLCA,6.0,0.215686275,inflamed,NR,"In a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression from a kidney biopsy, and with a tumor mutational burden of 6.0, is treatment with atezolizumab likely to be effective?","In a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression from a kidney biopsy, and with a tumor mutational burden of 6.0, is treatment with atezolizumab likely to be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/76a431-ar-76a431b.pkl. "
BLCA,,0.215686275,inflamed,R,"I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression profile was obtained from a bladder biopsy to assess the tumor immune microenvironment. Although his tumor mutational burden (TMB) is not available, I am considering treatment with Atezolizumab. Based on this information, how likely is he to respond to this therapy?","I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression profile was obtained from a bladder biopsy to assess the tumor immune microenvironment. Although his tumor mutational burden (TMB) is not available, I am considering treatment with Atezolizumab. Based on this information, how likely is he to respond to this therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/771445-ar-771445e.pkl. "
BLCA,3.0,0.745098039,inflamed,NR,"For a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 3.0 and mRNA TPM expression data from a bladder biopsy assessing the tumor immune microenvironment, how likely is it that he would respond to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 3.0 and mRNA TPM expression data from a bladder biopsy assessing the tumor immune microenvironment, how likely is it that he would respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7829a3-ar-7829a34.pkl. "
BLCA,5.0,0.941176471,,NR,"In a male patient with bladder urothelial carcinoma, a bladder biopsy demonstrated mRNA TPM expression indicative of the tumor immune microenvironment, and a tumor mutational burden of 5.0 was observed. Given these findings, is it likely that the patient will respond to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, a bladder biopsy demonstrated mRNA TPM expression indicative of the tumor immune microenvironment, and a tumor mutational burden of 5.0 was observed. Given these findings, is it likely that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/789319-ar-7893196.pkl. "
BLCA,,1.039215686,excluded,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy was assessed to evaluate the tumor immune microenvironment, and the tumor mutational burden (TMB) is not available. Given these factors, what is the likelihood that the patient will benefit from Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy was assessed to evaluate the tumor immune microenvironment, and the tumor mutational burden (TMB) is not available. Given these factors, what is the likelihood that the patient will benefit from Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7aa01f-ar-7aa01fc.pkl. "
BLCA,12.0,,,R,"I have a female patient with bladder urothelial carcinoma who underwent a ureter biopsy for mRNA TPM expression analysis to assess the tumor immune microenvironment. With a tumor mutational burden of 12, what is the likelihood that she will respond to Atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma who underwent a ureter biopsy for mRNA TPM expression analysis to assess the tumor immune microenvironment. With a tumor mutational burden of 12, what is the likelihood that she will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7b4000-ar-7b40007.pkl. "
BLCA,,0.725490196,,NR,"I have a male patient with bladder urothelial carcinoma whose tumor mRNA expression (TPM) was assessed via a ureter biopsy to evaluate the immune microenvironment, but the tumor mutational burden reading was non-numeric. Based on these findings, is there evidence to suggest that the patient is likely to respond to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose tumor mRNA expression (TPM) was assessed via a ureter biopsy to evaluate the immune microenvironment, but the tumor mutational burden reading was non-numeric. Based on these findings, is there evidence to suggest that the patient is likely to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7bff23-ar-7bff231.pkl. "
BLCA,5.0,0.529411765,,NR,"A female patient with bladder urothelial carcinoma has had her mRNA TPM expression evaluated from a bladder biopsy to assess the tumor immune microenvironment, and her tumor mutational burden is 5.0. Given these findings, what is the likelihood that she will respond to Atezolizumab therapy?","A female patient with bladder urothelial carcinoma has had her mRNA TPM expression evaluated from a bladder biopsy to assess the tumor immune microenvironment, and her tumor mutational burden is 5.0. Given these findings, what is the likelihood that she will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7c67b0-ar-7c67b05.pkl. "
BLCA,4.0,0.156862745,inflamed,NR,"For a male patient with bladder urothelial carcinoma, we obtained mRNA TPM expression data from a lymph node biopsy to evaluate the tumor immune microenvironment. Considering his tumor mutational burden of 4.0, is he likely to respond to treatment with atezolizumab?","For a male patient with bladder urothelial carcinoma, we obtained mRNA TPM expression data from a lymph node biopsy to evaluate the tumor immune microenvironment. Considering his tumor mutational burden of 4.0, is he likely to respond to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7d2dfb-ar-7d2dfba.pkl. "
BLCA,8.0,2.098039216,excluded,R,"For a male patient with bladder urothelial carcinoma, tumor mRNA TPM expression from a bladder biopsy was used to assess the immune microenvironment, and his tumor mutational burden is 8.0 mutations/Mb. Based on these factors, how likely is it that the patient will respond favorably to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma, tumor mRNA TPM expression from a bladder biopsy was used to assess the immune microenvironment, and his tumor mutational burden is 8.0 mutations/Mb. Based on these factors, how likely is it that the patient will respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7d7c54-ar-7d7c546.pkl. "
BLCA,,,excluded,NR,"In a male patient with bladder urothelial carcinoma whose tumor immune microenvironment has been characterized using mRNA TPM expression from a bladder biopsy, and with tumor mutational burden data unavailable, how likely is he to respond to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma whose tumor immune microenvironment has been characterized using mRNA TPM expression from a bladder biopsy, and with tumor mutational burden data unavailable, how likely is he to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7f0d9c-ar-7f0d9cc.pkl. "
BLCA,1.0,,excluded,NR,"For a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy was obtained to evaluate the tumor immune microenvironment, and his tumor mutational burden is 1.0. Given these factors, is the patient likely to benefit from treatment with atezolizumab?","For a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy was obtained to evaluate the tumor immune microenvironment, and his tumor mutational burden is 1.0. Given these factors, is the patient likely to benefit from treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7fb698-ar-7fb6987.pkl. "
BLCA,11.0,0.764705882,excluded,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression profiling from a kidney biopsy was used to assess the tumor immune microenvironment, and the tumor exhibits a mutational burden of 11.0. Given these findings, how likely is the patient to respond to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression profiling from a kidney biopsy was used to assess the tumor immune microenvironment, and the tumor exhibits a mutational burden of 11.0. Given these findings, how likely is the patient to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7fb7a1-ar-7fb7a13.pkl. "
BLCA,8.0,0.215686275,inflamed,NR,"A male patient with bladder urothelial carcinoma underwent a kidney biopsy for mRNA TPM expression analysis to evaluate the tumor immune microenvironment. The tumor demonstrates a mutational burden of 8.0 mutations per megabase. Based on these findings, is it likely that the patient will respond to Atezolizumab therapy?","A male patient with bladder urothelial carcinoma underwent a kidney biopsy for mRNA TPM expression analysis to evaluate the tumor immune microenvironment. The tumor demonstrates a mutational burden of 8.0 mutations per megabase. Based on these findings, is it likely that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/80c618-ar-80c6183.pkl. "
BLCA,7.0,1.078431373,,NR,"For a female patient with bladder urothelial carcinoma, where mRNA TPM expression from a bladder biopsy was used to assess the tumor immune microenvironment and the tumor mutational burden is 7.0, would Atezolizumab be an effective treatment option?","For a female patient with bladder urothelial carcinoma, where mRNA TPM expression from a bladder biopsy was used to assess the tumor immune microenvironment and the tumor mutational burden is 7.0, would Atezolizumab be an effective treatment option?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/81b715-ar-81b7152.pkl. "
BLCA,,1.098039216,desert,NR,"I have a male patient with bladder urothelial carcinoma who recently underwent a biopsy with mRNA TPM expression analysis to evaluate the tumor immune microenvironment. However, the tumor mutational burden data is not available. Given these findings, would this patient be a suitable candidate for Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma who recently underwent a biopsy with mRNA TPM expression analysis to evaluate the tumor immune microenvironment. However, the tumor mutational burden data is not available. Given these findings, would this patient be a suitable candidate for Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/822b22-ar-822b226.pkl. "
BLCA,5.0,1.725490196,desert,R,"For a male patient diagnosed with bladder urothelial carcinoma who has a tumor mutational burden (TMB) of 5.0 and mRNA TPM expression data from a bladder biopsy evaluating the tumor immune microenvironment, how likely is he to respond to Atezolizumab therapy?","For a male patient diagnosed with bladder urothelial carcinoma who has a tumor mutational burden (TMB) of 5.0 and mRNA TPM expression data from a bladder biopsy evaluating the tumor immune microenvironment, how likely is he to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8533e5-ar-8533e5e.pkl. "
BLCA,8.0,0.274509804,excluded,NR,Does this male patient with bladder urothelial carcinoma—whose mRNA TPM expression was measured from a lung biopsy to evaluate the tumor immune microenvironment and who has a tumor mutational burden of 8.0—appear likely to respond to Atezolizumab therapy?,Does this male patient with bladder urothelial carcinoma—whose mRNA TPM expression was measured from a lung biopsy to evaluate the tumor immune microenvironment and who has a tumor mutational burden of 8.0—appear likely to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/85f0a3-ar-85f0a3a.pkl. 
BLCA,14.0,0.31372549,excluded,NR,"In a female patient with bladder urothelial carcinoma, the tumor mutational burden is 14.0, and mRNA TPM expression from a bladder biopsy has been evaluated to assess the tumor immune microenvironment. Would these factors suggest a potential for a favorable response to Atezolizumab therapy?","In a female patient with bladder urothelial carcinoma, the tumor mutational burden is 14.0, and mRNA TPM expression from a bladder biopsy has been evaluated to assess the tumor immune microenvironment. Would these factors suggest a potential for a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/87a8e1-ar-87a8e18.pkl. "
BLCA,13.0,6.0,inflamed,R,"In a male patient with bladder urothelial carcinoma whose bladder biopsy shows mRNA TPM expression profiling indicative of the tumor immune microenvironment, and with a tumor mutational burden of 13.0, how likely is it that he will respond to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma whose bladder biopsy shows mRNA TPM expression profiling indicative of the tumor immune microenvironment, and with a tumor mutational burden of 13.0, how likely is it that he will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8884fe-ar-8884fe4.pkl. "
BLCA,14.0,0.843137255,desert,R,"For a male patient with bladder urothelial carcinoma, whose bladder biopsy shows specific mRNA TPM expression related to the tumor immune microenvironment and a tumor mutational burden of 14.0, how likely is it that he would respond favorably to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma, whose bladder biopsy shows specific mRNA TPM expression related to the tumor immune microenvironment and a tumor mutational burden of 14.0, how likely is it that he would respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8a1b0e-ar-8a1b0e0.pkl. "
BLCA,7.0,1.0,excluded,NR,"In a male patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment has been evaluated using mRNA TPM expression analysis from a kidney biopsy and who has a tumor mutational burden (TMB) of 7.0, would you expect a favorable response to treatment with Atezolizumab?","In a male patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment has been evaluated using mRNA TPM expression analysis from a kidney biopsy and who has a tumor mutational burden (TMB) of 7.0, would you expect a favorable response to treatment with Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8b4b8b-ar-8b4b8b0.pkl. "
BLCA,6.0,,excluded,NR,"Given that this male patient with bladder urothelial carcinoma has a tumor mutational burden of 6.0 and an mRNA TPM expression profile derived from a bladder biopsy to assess the tumor immune microenvironment, how likely is he to respond to Atezolizumab therapy?","Given that this male patient with bladder urothelial carcinoma has a tumor mutational burden of 6.0 and an mRNA TPM expression profile derived from a bladder biopsy to assess the tumor immune microenvironment, how likely is he to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8e4698-ar-8e46983.pkl. "
BLCA,6.0,0.509803922,desert,NR,"In a male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 6.0 and available mRNA TPM expression data from a kidney biopsy evaluating the tumor immune microenvironment, would treatment with Atezolizumab likely be effective?","In a male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 6.0 and available mRNA TPM expression data from a kidney biopsy evaluating the tumor immune microenvironment, would treatment with Atezolizumab likely be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8e8ef2-ar-8e8ef23.pkl. "
BLCA,5.0,,desert,NR,"In a male patient diagnosed with bladder urothelial carcinoma, the mRNA TPM expression from a bladder biopsy has been used to evaluate the tumor immune microenvironment, and the tumor mutational burden is 5.0. Considering these factors, what is the likelihood that the patient will respond to atezolizumab therapy?","In a male patient diagnosed with bladder urothelial carcinoma, the mRNA TPM expression from a bladder biopsy has been used to evaluate the tumor immune microenvironment, and the tumor mutational burden is 5.0. Considering these factors, what is the likelihood that the patient will respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8f2275-ar-8f2275c.pkl. "
BLCA,49.0,2.705882353,inflamed,R,"For a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 49, and whose mRNA TPM expression from a bladder biopsy indicates characteristics of the tumor immune microenvironment, is there evidence to support a likely response to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 49, and whose mRNA TPM expression from a bladder biopsy indicates characteristics of the tumor immune microenvironment, is there evidence to support a likely response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/91c47b-ar-91c47b0.pkl. "
BLCA,12.0,2.235294118,inflamed,NR,"For a patient with bladder urothelial carcinoma whose tumor biopsy shows an mRNA TPM expression profile of the tumor immune microenvironment and a tumor mutational burden of 12.0, is there evidence to suggest that treatment with atezolizumab would be effective?","For a patient with bladder urothelial carcinoma whose tumor biopsy shows an mRNA TPM expression profile of the tumor immune microenvironment and a tumor mutational burden of 12.0, is there evidence to suggest that treatment with atezolizumab would be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9306c5-ar-9306c5c.pkl. "
BLCA,,,,NR,"I have a male patient with bladder urothelial carcinoma for whom we assessed the tumor immune microenvironment using mRNA TPM expression from a bladder biopsy, and the tumor mutational burden is reported as non-numerical. Given these factors, how likely is the patient to respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma for whom we assessed the tumor immune microenvironment using mRNA TPM expression from a bladder biopsy, and the tumor mutational burden is reported as non-numerical. Given these factors, how likely is the patient to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9410b8-ar-9410b86.pkl. "
BLCA,5.0,0.117647059,desert,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression analysis from a bladder biopsy indicates a specific tumor immune microenvironment, and the tumor mutational burden is 5.0. Based on these findings, how likely is the patient to respond to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression analysis from a bladder biopsy indicates a specific tumor immune microenvironment, and the tumor mutational burden is 5.0. Based on these findings, how likely is the patient to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/943df5-ar-943df5c.pkl. "
BLCA,11.0,0.215686275,excluded,NR,"We have a male patient with bladder urothelial carcinoma whose tumor mRNA TPM expression from a kidney biopsy was analyzed to evaluate the immune microenvironment, and his tumor mutational burden is 11.0. Based on these parameters, how likely is he to respond to Atezolizumab therapy?","We have a male patient with bladder urothelial carcinoma whose tumor mRNA TPM expression from a kidney biopsy was analyzed to evaluate the immune microenvironment, and his tumor mutational burden is 11.0. Based on these parameters, how likely is he to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/94859b-ar-94859b4.pkl. "
BLCA,,0.431372549,desert,NR,"I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was evaluated from a biopsy to characterize the tumor immune microenvironment, but his tumor mutational burden (TMB) data is unavailable. Based on these findings, how likely is he to respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was evaluated from a biopsy to characterize the tumor immune microenvironment, but his tumor mutational burden (TMB) data is unavailable. Based on these findings, how likely is he to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9539a4-ar-9539a4f.pkl. "
BLCA,,0.196078431,excluded,NR,"I have a male patient with bladder urothelial carcinoma for whom we obtained mRNA TPM expression data from a ureteral biopsy to evaluate the tumor immune microenvironment. His tumor mutational burden is reported as unavailable (nan). Given these findings, how likely is he to respond to treatment with Atezolizumab?","I have a male patient with bladder urothelial carcinoma for whom we obtained mRNA TPM expression data from a ureteral biopsy to evaluate the tumor immune microenvironment. His tumor mutational burden is reported as unavailable (nan). Given these findings, how likely is he to respond to treatment with Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/957378-ar-957378b.pkl. "
BLCA,17.0,1.725490196,excluded,NR,"For a male patient with bladder urothelial carcinoma whose bladder biopsy shows mRNA expression (TPM) profiling of the tumor immune microenvironment and a tumor mutational burden of 17.0, would you expect him to benefit from treatment with atezolizumab?","For a male patient with bladder urothelial carcinoma whose bladder biopsy shows mRNA expression (TPM) profiling of the tumor immune microenvironment and a tumor mutational burden of 17.0, would you expect him to benefit from treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/961d04-ar-961d04c.pkl. "
BLCA,22.0,4.431372549,desert,NR,"In a male patient with bladder urothelial carcinoma, who has undergone mRNA TPM expression profiling of a bladder biopsy to evaluate the tumor immune microenvironment, and with a tumor mutational burden of 22.0, would treatment with Atezolizumab be expected to yield a favorable response?","In a male patient with bladder urothelial carcinoma, who has undergone mRNA TPM expression profiling of a bladder biopsy to evaluate the tumor immune microenvironment, and with a tumor mutational burden of 22.0, would treatment with Atezolizumab be expected to yield a favorable response?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/972530-ar-9725303.pkl. "
BLCA,,1.921568627,excluded,NR,"I have a male patient with bladder urothelial carcinoma (BLCA) whose tumor mRNA TPM expression was assessed via biopsy to evaluate the immune microenvironment. However, his tumor mutational burden (TMB) data is not available. Based on these findings, is he likely to respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma (BLCA) whose tumor mRNA TPM expression was assessed via biopsy to evaluate the immune microenvironment. However, his tumor mutational burden (TMB) data is not available. Based on these findings, is he likely to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/978a58-ar-978a587.pkl. "
BLCA,18.0,2.862745098,excluded,R,"I have a male patient with bladder urothelial carcinoma, and immunogenomic profiling—including mRNA TPM expression analysis from a kidney biopsy—has been performed to assess the tumor immune microenvironment. The tumor exhibits a mutational burden of 18.0. Based on these factors, what is the likelihood that the patient will respond to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma, and immunogenomic profiling—including mRNA TPM expression analysis from a kidney biopsy—has been performed to assess the tumor immune microenvironment. The tumor exhibits a mutational burden of 18.0. Based on these factors, what is the likelihood that the patient will respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/97a00e-ar-97a00e0.pkl. "
BLCA,5.0,0.725490196,excluded,NR,"I have a male patient with bladder urothelial carcinoma whose tumor mRNA expression was quantified using TPM from a kidney biopsy to evaluate the tumor immune microenvironment. The tumor mutational burden is 5.0, and I am considering Atezolizumab as a treatment option. Based on these parameters, is it likely that he will respond favorably to this therapy?","I have a male patient with bladder urothelial carcinoma whose tumor mRNA expression was quantified using TPM from a kidney biopsy to evaluate the tumor immune microenvironment. The tumor mutational burden is 5.0, and I am considering Atezolizumab as a treatment option. Based on these parameters, is it likely that he will respond favorably to this therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/99a46b-ar-99a46b9.pkl. "
BLCA,4.0,0.862745098,inflamed,NR,"For a male patient with bladder urothelial carcinoma, whose mRNA TPM expression from a bladder biopsy has been used to assess the tumor immune microenvironment and has a tumor mutational burden of 4.0, is it likely that treatment with Atezolizumab would result in a favorable response?","For a male patient with bladder urothelial carcinoma, whose mRNA TPM expression from a bladder biopsy has been used to assess the tumor immune microenvironment and has a tumor mutational burden of 4.0, is it likely that treatment with Atezolizumab would result in a favorable response?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9a2cf3-ar-9a2cf3c.pkl. "
BLCA,5.0,0.647058824,excluded,NR,"I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression, obtained from a kidney biopsy to evaluate the tumor immune microenvironment, reveals a tumor mutational burden of 5.0. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression, obtained from a kidney biopsy to evaluate the tumor immune microenvironment, reveals a tumor mutational burden of 5.0. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9aa6a0-ar-9aa6a09.pkl. "
BLCA,12.0,0.588235294,inflamed,NR,"I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was measured from a kidney biopsy to evaluate the tumor immune microenvironment, and his tumor mutational burden is 12.0. Based on these parameters, would he be likely to respond to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was measured from a kidney biopsy to evaluate the tumor immune microenvironment, and his tumor mutational burden is 12.0. Based on these parameters, would he be likely to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9cafb9-ar-9cafb90.pkl. "
BLCA,,,,NR,In a male patient with bladder urothelial carcinoma who underwent mRNA TPM expression analysis from a liver biopsy to evaluate the tumor immune microenvironment—with an unavailable tumor mutational burden—would initiating atezolizumab therapy be expected to yield a favorable response?,In a male patient with bladder urothelial carcinoma who underwent mRNA TPM expression analysis from a liver biopsy to evaluate the tumor immune microenvironment—with an unavailable tumor mutational burden—would initiating atezolizumab therapy be expected to yield a favorable response?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9d2494-ar-9d24941.pkl. 
BLCA,,,desert,NR,"A female patient diagnosed with bladder urothelial carcinoma has had her tumor immune microenvironment assessed via mRNA TPM expression from a kidney biopsy, and her tumor mutational burden is reported as “nan.” Given these findings, what is the likelihood that she will respond to Atezolizumab therapy?","A female patient diagnosed with bladder urothelial carcinoma has had her tumor immune microenvironment assessed via mRNA TPM expression from a kidney biopsy, and her tumor mutational burden is reported as “nan.” Given these findings, what is the likelihood that she will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9dacca-ar-9daccaf.pkl. "
BLCA,10.0,,inflamed,NR,"In a patient with bladder urothelial carcinoma whose bladder biopsy mRNA TPM expression profile was assessed for the tumor immune microenvironment and who has a tumor mutational burden of 10, is Atezolizumab likely to be effective?","In a patient with bladder urothelial carcinoma whose bladder biopsy mRNA TPM expression profile was assessed for the tumor immune microenvironment and who has a tumor mutational burden of 10, is Atezolizumab likely to be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9e11ec-ar-9e11ec6.pkl. "
BLCA,6.0,0.431372549,desert,NR,"Given a female patient with bladder urothelial carcinoma whose bladder biopsy analysis includes mRNA TPM expression for evaluating the tumor immune microenvironment, and with a tumor mutational burden of 6.0, would you expect a favorable response to Atezolizumab therapy?","Given a female patient with bladder urothelial carcinoma whose bladder biopsy analysis includes mRNA TPM expression for evaluating the tumor immune microenvironment, and with a tumor mutational burden of 6.0, would you expect a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9fb814-ar-9fb814c.pkl. "
BLCA,,3.333333333,desert,NR,"In a female patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy was used to assess the tumor immune microenvironment, but the tumor mutational burden (TMB) data are not available. Based on this information, how likely is she to respond to Atezolizumab therapy?","In a female patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy was used to assess the tumor immune microenvironment, but the tumor mutational burden (TMB) data are not available. Based on this information, how likely is she to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a1871f-ar-a1871f4.pkl. "
BLCA,15.0,0.921568627,inflamed,NR,"In a female patient with bladder urothelial carcinoma, whose tumor immune microenvironment was evaluated via mRNA TPM expression analysis from a bladder biopsy and who presents with a tumor mutational burden of 15.0, what is the likelihood that she would respond favorably to Atezolizumab?","In a female patient with bladder urothelial carcinoma, whose tumor immune microenvironment was evaluated via mRNA TPM expression analysis from a bladder biopsy and who presents with a tumor mutational burden of 15.0, what is the likelihood that she would respond favorably to Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a1e62d-ar-a1e62d3.pkl. "
BLCA,8.0,1.411764706,excluded,NR,"I have a male patient with bladder urothelial carcinoma whose lymph node biopsy revealed specific mRNA TPM expression to evaluate the tumor immune microenvironment, and his tumor mutational burden is 8.0. Based on these findings, what is the likelihood of a positive response to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose lymph node biopsy revealed specific mRNA TPM expression to evaluate the tumor immune microenvironment, and his tumor mutational burden is 8.0. Based on these findings, what is the likelihood of a positive response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a32177-ar-a321770.pkl. "
BLCA,6.0,0.68627451,,NR,"In a male patient with bladder urothelial carcinoma and a tumor mutational burden of 6.0, mRNA TPM expression profiling from a bladder biopsy has been performed to assess the tumor immune microenvironment. Given these findings, what is the likelihood that the patient will respond to atezolizumab therapy?","In a male patient with bladder urothelial carcinoma and a tumor mutational burden of 6.0, mRNA TPM expression profiling from a bladder biopsy has been performed to assess the tumor immune microenvironment. Given these findings, what is the likelihood that the patient will respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a424c7-ar-a424c75.pkl. "
BLCA,19.0,0.882352941,,R,"For a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 19.0 and mRNA TPM expression data from a bladder biopsy reflecting the tumor immune microenvironment, what is the likelihood of a positive response to atezolizumab therapy?","For a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 19.0 and mRNA TPM expression data from a bladder biopsy reflecting the tumor immune microenvironment, what is the likelihood of a positive response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a535fc-ar-a535fcd.pkl. "
BLCA,12.0,0.725490196,,NR,"I have a male patient with bladder urothelial carcinoma whose tumor mutational burden is 12, and we have mRNA TPM expression data from a biopsy assessing the tumor immune microenvironment. Would you expect this patient to respond favorably to treatment with atezolizumab?","I have a male patient with bladder urothelial carcinoma whose tumor mutational burden is 12, and we have mRNA TPM expression data from a biopsy assessing the tumor immune microenvironment. Would you expect this patient to respond favorably to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a90d73-ar-a90d73f.pkl. "
BLCA,,1.529411765,excluded,NR,"I have a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression from a kidney biopsy. The tumor mutational burden (TMB) is reported as nan. Given these factors, how likely is it that he will respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression from a kidney biopsy. The tumor mutational burden (TMB) is reported as nan. Given these factors, how likely is it that he will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a913c6-ar-a913c61.pkl. "
BLCA,3.0,0.352941176,,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy was obtained to evaluate the tumor immune microenvironment, and the tumor mutational burden is 3.0. Based on these factors, how likely is he to respond to atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy was obtained to evaluate the tumor immune microenvironment, and the tumor mutational burden is 3.0. Based on these factors, how likely is he to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a9ca85-ar-a9ca853.pkl. "
BLCA,18.0,2.0,,NR,"I have a male patient with bladder urothelial carcinoma who underwent a lymph node biopsy for mRNA TPM assessment of the tumor immune microenvironment, and his tumor mutational burden is 18. With these findings in mind, would you consider Atezolizumab a promising treatment option for him?","I have a male patient with bladder urothelial carcinoma who underwent a lymph node biopsy for mRNA TPM assessment of the tumor immune microenvironment, and his tumor mutational burden is 18. With these findings in mind, would you consider Atezolizumab a promising treatment option for him?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/aabf4a-ar-aabf4af.pkl. "
BLCA,15.0,1.725490196,excluded,R,"For my male patient with bladder urothelial carcinoma (BLCA), we obtained mRNA TPM expression data from a kidney biopsy to evaluate the tumor immune microenvironment. With a tumor mutational burden of 15.0, do you think he is likely to benefit from Atezolizumab therapy?","For my male patient with bladder urothelial carcinoma (BLCA), we obtained mRNA TPM expression data from a kidney biopsy to evaluate the tumor immune microenvironment. With a tumor mutational burden of 15.0, do you think he is likely to benefit from Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/aaf505-ar-aaf505c.pkl. "
BLCA,,0.039215686,inflamed,NR,"For a male patient with bladder urothelial carcinoma (BLCA), whose tumor immune microenvironment was evaluated via mRNA TPM expression from a lymph node biopsy and with an indeterminate tumor mutational burden, would Atezolizumab be an appropriate therapeutic option based on these findings?","For a male patient with bladder urothelial carcinoma (BLCA), whose tumor immune microenvironment was evaluated via mRNA TPM expression from a lymph node biopsy and with an indeterminate tumor mutational burden, would Atezolizumab be an appropriate therapeutic option based on these findings?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ab8052-ar-ab8052a.pkl. "
BLCA,,,excluded,NR,"I have a female patient with bladder urothelial carcinoma whose tumor immune microenvironment was assessed using mRNA TPM expression profiling from a bladder biopsy. The tumor mutational burden was reported as not available (nan). Given these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma whose tumor immune microenvironment was assessed using mRNA TPM expression profiling from a bladder biopsy. The tumor mutational burden was reported as not available (nan). Given these findings, what is the likelihood of a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/abc151-ar-abc151b.pkl. "
BLCA,6.0,0.745098039,,NR,"In a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 6.0 and mRNA TPM expression data obtained from a kidney biopsy to evaluate the tumor immune microenvironment, is there evidence supporting the likelihood of a response to atezolizumab therapy?","In a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 6.0 and mRNA TPM expression data obtained from a kidney biopsy to evaluate the tumor immune microenvironment, is there evidence supporting the likelihood of a response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ad83c9-ar-ad83c9c.pkl. "
BLCA,,,,NR,"In a female patient with bladder urothelial carcinoma, where mRNA TPM expression from a kidney biopsy was used to assess the tumor immune microenvironment and the tumor mutational burden is reported as 'nan', how likely is it that she would respond to atezolizumab therapy?","In a female patient with bladder urothelial carcinoma, where mRNA TPM expression from a kidney biopsy was used to assess the tumor immune microenvironment and the tumor mutational burden is reported as 'nan', how likely is it that she would respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ae0262-ar-ae02629.pkl. "
BLCA,,,,NR,"I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was analyzed from a ureter biopsy to assess the tumor immune microenvironment. The tumor mutational burden data is not available. Based on these factors, is the patient likely to respond to Atezolizumab?","I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was analyzed from a ureter biopsy to assess the tumor immune microenvironment. The tumor mutational burden data is not available. Based on these factors, is the patient likely to respond to Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ae1690-ar-ae16904.pkl. "
BLCA,,,,NR,"I have a female patient with bladder urothelial carcinoma who underwent a bladder biopsy for mRNA TPM expression analysis to evaluate the tumor immune microenvironment. Her tumor mutational burden data is not available. Based on these findings, how likely is she to respond to Atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma who underwent a bladder biopsy for mRNA TPM expression analysis to evaluate the tumor immune microenvironment. Her tumor mutational burden data is not available. Based on these findings, how likely is she to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ae4da2-ar-ae4da27.pkl. "
BLCA,4.0,,excluded,R,"For a male patient with bladder urothelial carcinoma whose mRNA expression profile from a ureter biopsy has been characterized for the tumor immune microenvironment and who has a tumor mutational burden of 4.0, would Atezolizumab be expected to provide a therapeutic benefit?","For a male patient with bladder urothelial carcinoma whose mRNA expression profile from a ureter biopsy has been characterized for the tumor immune microenvironment and who has a tumor mutational burden of 4.0, would Atezolizumab be expected to provide a therapeutic benefit?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/aec738-ar-aec7380.pkl. "
BLCA,14.0,2.196078431,inflamed,NR,"In a male patient with bladder urothelial carcinoma, where mRNA expression profiling from a bladder biopsy indicates evaluation of the tumor immune microenvironment and the tumor mutational burden is 14.0, how likely is the patient to respond favorably to atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, where mRNA expression profiling from a bladder biopsy indicates evaluation of the tumor immune microenvironment and the tumor mutational burden is 14.0, how likely is the patient to respond favorably to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/af42c1-ar-af42c15.pkl. "
BLCA,7.0,0.352941176,,NR,"For a male patient with bladder urothelial carcinoma, mRNA TPM expression from a lung biopsy was used to evaluate the tumor immune microenvironment, and his tumor mutational burden (TMB) is 7.0. Given these findings, would treatment with Atezolizumab be expected to result in a favorable clinical response?","For a male patient with bladder urothelial carcinoma, mRNA TPM expression from a lung biopsy was used to evaluate the tumor immune microenvironment, and his tumor mutational burden (TMB) is 7.0. Given these findings, would treatment with Atezolizumab be expected to result in a favorable clinical response?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b0a83e-ar-b0a83e5.pkl. "
BLCA,3.0,0.843137255,inflamed,NR,"I have a female patient with bladder urothelial carcinoma who underwent a lung biopsy, and her mRNA TPM expression was analyzed to assess the tumor immune microenvironment. Given that her tumor mutational burden is 3.0, how likely is she to respond to Atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma who underwent a lung biopsy, and her mRNA TPM expression was analyzed to assess the tumor immune microenvironment. Given that her tumor mutational burden is 3.0, how likely is she to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b0d11d-ar-b0d11db.pkl. "
BLCA,11.0,1.509803922,,R,"In a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 11.0 and mRNA TPM expression profiling from his bladder biopsy was performed to assess the tumor immune microenvironment, how likely is it that he will respond to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 11.0 and mRNA TPM expression profiling from his bladder biopsy was performed to assess the tumor immune microenvironment, how likely is it that he will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b15ac6-ar-b15ac6e.pkl. "
BLCA,4.0,,excluded,NR,"In a female patient with bladder urothelial carcinoma, where mRNA TPM expression from a bladder biopsy has been used to evaluate the tumor immune microenvironment and the tumor mutational burden is 4.0, how likely is she to respond to atezolizumab therapy?","In a female patient with bladder urothelial carcinoma, where mRNA TPM expression from a bladder biopsy has been used to evaluate the tumor immune microenvironment and the tumor mutational burden is 4.0, how likely is she to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b15ad0-ar-b15ad09.pkl. "
BLCA,,,,NR,"In a female patient with bladder urothelial carcinoma, mRNA TPM expression was evaluated from a bladder biopsy to assess the tumor immune microenvironment; however, the tumor mutational burden (TMB) result is unavailable (nan). Given these findings, what is the likelihood that she will respond to Atezolizumab therapy?","In a female patient with bladder urothelial carcinoma, mRNA TPM expression was evaluated from a bladder biopsy to assess the tumor immune microenvironment; however, the tumor mutational burden (TMB) result is unavailable (nan). Given these findings, what is the likelihood that she will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b2e4a0-ar-b2e4a08.pkl. "
BLCA,,0.862745098,desert,R,"Given a patient with bladder urothelial carcinoma in whom mRNA TPM expression from a bladder biopsy was used to assess the tumor immune microenvironment, and with an indeterminate tumor mutational burden (recorded as ""nan""), how likely is it that the patient will respond to Atezolizumab therapy?","Given a patient with bladder urothelial carcinoma in whom mRNA TPM expression from a bladder biopsy was used to assess the tumor immune microenvironment, and with an indeterminate tumor mutational burden (recorded as ""nan""), how likely is it that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b2f1d0-ar-b2f1d0e.pkl. "
BLCA,18.0,,desert,R,"Given a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 18.0 and mRNA TPM expression analysis from an alternative biopsy assessing the tumor immune microenvironment, what is the expected likelihood of a favorable response to atezolizumab therapy?","Given a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 18.0 and mRNA TPM expression analysis from an alternative biopsy assessing the tumor immune microenvironment, what is the expected likelihood of a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b3c022-ar-b3c0229.pkl. "
BLCA,19.0,,excluded,R,"In a male patient with bladder urothelial carcinoma whose bladder biopsy revealed an mRNA TPM expression profile to assess the tumor immune microenvironment and a tumor mutational burden of 19.0, would treatment with Atezolizumab be expected to yield a favorable therapeutic response?","In a male patient with bladder urothelial carcinoma whose bladder biopsy revealed an mRNA TPM expression profile to assess the tumor immune microenvironment and a tumor mutational burden of 19.0, would treatment with Atezolizumab be expected to yield a favorable therapeutic response?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b419a8-ar-b419a8f.pkl. "
BLCA,35.0,,excluded,R,"The patient has bladder urothelial carcinoma, with tumor mRNA TPM expression measured via biopsy and a tumor mutational burden of 35.0. Would these findings suggest that the patient is likely to respond favorably to atezolizumab therapy?","The patient has bladder urothelial carcinoma, with tumor mRNA TPM expression measured via biopsy and a tumor mutational burden of 35.0. Would these findings suggest that the patient is likely to respond favorably to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b470eb-ar-b470eb8.pkl. "
BLCA,5.0,,inflamed,NR,"In a male patient with bladder urothelial carcinoma (BLCA), mRNA TPM expression from a kidney biopsy was evaluated to characterize the tumor immune microenvironment, and the tumor mutational burden (TMB) is 5.0. Based on these findings, would you anticipate a favorable response to atezolizumab therapy?","In a male patient with bladder urothelial carcinoma (BLCA), mRNA TPM expression from a kidney biopsy was evaluated to characterize the tumor immune microenvironment, and the tumor mutational burden (TMB) is 5.0. Based on these findings, would you anticipate a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b4c7a0-ar-b4c7a00.pkl. "
BLCA,5.0,0.333333333,desert,NR,"For a patient with bladder urothelial carcinoma, with mRNA TPM expression measured from a bladder biopsy and a tumor mutational burden of 5.0, how likely is it that they will respond to atezolizumab therapy?","For a patient with bladder urothelial carcinoma, with mRNA TPM expression measured from a bladder biopsy and a tumor mutational burden of 5.0, how likely is it that they will respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b8070b-ar-b8070b7.pkl. "
BLCA,16.0,3.764705882,inflamed,NR,"In a male patient with bladder urothelial carcinoma who has undergone biopsy yielding tumor mRNA TPM expression data and exhibits a tumor mutational burden of 16.0, how does this profile inform the likelihood of a favorable response to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma who has undergone biopsy yielding tumor mRNA TPM expression data and exhibits a tumor mutational burden of 16.0, how does this profile inform the likelihood of a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b8101c-ar-b8101c5.pkl. "
BLCA,8.0,0.882352941,excluded,NR,"I am evaluating a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 8.0 and for whom mRNA TPM expression data was obtained from a bladder biopsy to assess the tumor immune microenvironment. Considering these factors, what is the likelihood that the patient will respond to Atezolizumab therapy?","I am evaluating a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 8.0 and for whom mRNA TPM expression data was obtained from a bladder biopsy to assess the tumor immune microenvironment. Considering these factors, what is the likelihood that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b963dd-ar-b963dda.pkl. "
BLCA,5.0,0.901960784,inflamed,NR,"I am evaluating a male patient with bladder urothelial carcinoma. His tumor mRNA expression (TPM) was measured from a bladder biopsy to assess the tumor immune microenvironment, and his tumor mutational burden (TMB) is 5.0. Based on these findings, is his likelihood of responding to Atezolizumab favorable?","I am evaluating a male patient with bladder urothelial carcinoma. His tumor mRNA expression (TPM) was measured from a bladder biopsy to assess the tumor immune microenvironment, and his tumor mutational burden (TMB) is 5.0. Based on these findings, is his likelihood of responding to Atezolizumab favorable?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ba1a34-ar-ba1a34b.pkl. "
BLCA,5.0,,excluded,NR,"We have a female patient diagnosed with bladder urothelial carcinoma who underwent a kidney biopsy for mRNA TPM expression profiling of the tumor immune microenvironment. With a tumor mutational burden of 5.0, can we expect Atezolizumab to be an effective treatment option for her?","We have a female patient diagnosed with bladder urothelial carcinoma who underwent a kidney biopsy for mRNA TPM expression profiling of the tumor immune microenvironment. With a tumor mutational burden of 5.0, can we expect Atezolizumab to be an effective treatment option for her?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ba7176-ar-ba7176a.pkl. "
BLCA,7.0,0.745098039,desert,NR,"In a female patient with bladder urothelial carcinoma who underwent a bladder biopsy to assess mRNA TPM expression of the tumor immune microenvironment and has a tumor mutational burden of 7.0, would treatment with Atezolizumab be expected to be effective?","In a female patient with bladder urothelial carcinoma who underwent a bladder biopsy to assess mRNA TPM expression of the tumor immune microenvironment and has a tumor mutational burden of 7.0, would treatment with Atezolizumab be expected to be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bc8dc3-ar-bc8dc3a.pkl. "
BLCA,,,excluded,NR,"I have a male patient with bladder urothelial carcinoma who recently underwent a bladder biopsy for mRNA TPM expression analysis of the tumor immune microenvironment. However, the tumor mutational burden (TMB) result came back as 'nan.' Given these findings, how might this impact his potential response to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma who recently underwent a bladder biopsy for mRNA TPM expression analysis of the tumor immune microenvironment. However, the tumor mutational burden (TMB) result came back as 'nan.' Given these findings, how might this impact his potential response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bcb07b-ar-bcb07ba.pkl. "
BLCA,9.0,,desert,NR,"For a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was assessed via mRNA TPM expression from a bladder biopsy and who has a tumor mutational burden (TMB) of 9.0, how likely is it that he will respond to treatment with atezolizumab?","For a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was assessed via mRNA TPM expression from a bladder biopsy and who has a tumor mutational burden (TMB) of 9.0, how likely is it that he will respond to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bcbc79-ar-bcbc795.pkl. "
BLCA,20.0,1.254901961,inflamed,NR,"In our female patient with bladder urothelial carcinoma, given her high tumor mutational burden (20 mutations per megabase) and mRNA expression profile from a bladder biopsy assessing the tumor immune microenvironment, is there evidence to suggest that she would likely respond favorably to Atezolizumab therapy?","In our female patient with bladder urothelial carcinoma, given her high tumor mutational burden (20 mutations per megabase) and mRNA expression profile from a bladder biopsy assessing the tumor immune microenvironment, is there evidence to suggest that she would likely respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bda79f-ar-bda79f9.pkl. "
BLCA,10.0,0.784313725,excluded,NR,"I have a female patient with bladder urothelial carcinoma whose lymph node biopsy revealed mRNA TPM expression levels assessing the tumor immune microenvironment, and her tumor mutational burden is 10. Would these factors suggest a favorable response to atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma whose lymph node biopsy revealed mRNA TPM expression levels assessing the tumor immune microenvironment, and her tumor mutational burden is 10. Would these factors suggest a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/be83ea-ar-be83eae.pkl. "
BLCA,35.0,3.745098039,excluded,R,"In our patient with bladder urothelial carcinoma, mRNA TPM expression from the bladder biopsy has been used to assess the tumor immune microenvironment, and the tumor mutational burden is 35.0. Given these findings, is there evidence to suggest that the patient would be likely to respond favorably to Atezolizumab therapy?","In our patient with bladder urothelial carcinoma, mRNA TPM expression from the bladder biopsy has been used to assess the tumor immune microenvironment, and the tumor mutational burden is 35.0. Given these findings, is there evidence to suggest that the patient would be likely to respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bf1a3a-ar-bf1a3ae.pkl. "
BLCA,6.0,1.450980392,excluded,NR,"In a female patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy was evaluated to assess the tumor immune microenvironment, and her tumor mutational burden is 6.0 mutations/megabase. Based on these findings, is she likely to respond to Atezolizumab therapy?","In a female patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy was evaluated to assess the tumor immune microenvironment, and her tumor mutational burden is 6.0 mutations/megabase. Based on these findings, is she likely to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bfdffb-ar-bfdffb9.pkl. "
BLCA,3.0,0.294117647,desert,NR,"I have a female patient with bladder urothelial carcinoma who underwent a bladder biopsy for mRNA TPM expression analysis as part of the evaluation of her tumor immune microenvironment. Her tumor mutational burden is 3.0. Based on these factors, how likely is she to respond to Atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma who underwent a bladder biopsy for mRNA TPM expression analysis as part of the evaluation of her tumor immune microenvironment. Her tumor mutational burden is 3.0. Based on these factors, how likely is she to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c0d625-ar-c0d625a.pkl. "
BLCA,5.0,1.176470588,desert,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy was used to assess the tumor immune microenvironment, and the tumor mutational burden is 5.0. Based on these findings, how likely is the patient to respond to atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy was used to assess the tumor immune microenvironment, and the tumor mutational burden is 5.0. Based on these findings, how likely is the patient to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c0da5d-ar-c0da5d4.pkl. "
BLCA,5.0,0.960784314,desert,NR,"I have a male patient with bladder urothelial carcinoma who has undergone nano-biopsy mRNA TPM expression profiling to assess his tumor immune microenvironment and has a tumor mutational burden of 5.0. Considering these parameters, how likely is he to respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma who has undergone nano-biopsy mRNA TPM expression profiling to assess his tumor immune microenvironment and has a tumor mutational burden of 5.0. Considering these parameters, how likely is he to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c0ef41-ar-c0ef41a.pkl. "
BLCA,5.0,1.098039216,excluded,R,"We have a male patient with bladder urothelial carcinoma whose bladder biopsy revealed specific mRNA TPM expression data to characterize the tumor immune microenvironment, and the tumor mutational burden is 5.0. Based on these findings, what is the likelihood that the patient will respond to Atezolizumab therapy?","We have a male patient with bladder urothelial carcinoma whose bladder biopsy revealed specific mRNA TPM expression data to characterize the tumor immune microenvironment, and the tumor mutational burden is 5.0. Based on these findings, what is the likelihood that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c1251c-ar-c1251c7.pkl. "
BLCA,5.0,1.411764706,excluded,R,"In a patient diagnosed with bladder urothelial carcinoma, where mRNA TPM expression from a kidney biopsy was used to profile the tumor immune microenvironment and the tumor mutational burden is 5.0, how likely is the patient to respond to atezolizumab treatment?","In a patient diagnosed with bladder urothelial carcinoma, where mRNA TPM expression from a kidney biopsy was used to profile the tumor immune microenvironment and the tumor mutational burden is 5.0, how likely is the patient to respond to atezolizumab treatment?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c1b27b-ar-c1b27bc.pkl. "
BLCA,,,excluded,R,"In a male patient with bladder urothelial carcinoma, we obtained mRNA TPM expression data from a bladder biopsy to assess the tumor immune microenvironment, but the tumor mutational burden (TMB) value is unavailable (nan). Given these findings, what is the likelihood that the patient will respond to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, we obtained mRNA TPM expression data from a bladder biopsy to assess the tumor immune microenvironment, but the tumor mutational burden (TMB) value is unavailable (nan). Given these findings, what is the likelihood that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c2a182-ar-c2a1820.pkl. "
BLCA,3.0,0.196078431,desert,NR,"In a patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression from a bladder biopsy and who has a tumor mutational burden of 3.0, is Atezolizumab likely to be an effective treatment option?","In a patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression from a bladder biopsy and who has a tumor mutational burden of 3.0, is Atezolizumab likely to be an effective treatment option?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c57ead-ar-c57eadb.pkl. "
BLCA,10.0,,desert,NR,"I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was assessed from a ureter biopsy to evaluate his tumor immune microenvironment. With a tumor mutational burden of 10.0, would he be likely to respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was assessed from a ureter biopsy to evaluate his tumor immune microenvironment. With a tumor mutational burden of 10.0, would he be likely to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c69253-ar-c692536.pkl. "
BLCA,3.0,0.450980392,excluded,NR,"I am evaluating a male patient with bladder urothelial carcinoma whose tumor gene expression was assessed via mRNA TPM analysis from a lymph node biopsy to evaluate the tumor immune microenvironment. With a tumor mutational burden of 3.0 and considering treatment with Atezolizumab, is it likely that this patient will respond to this therapy?","I am evaluating a male patient with bladder urothelial carcinoma whose tumor gene expression was assessed via mRNA TPM analysis from a lymph node biopsy to evaluate the tumor immune microenvironment. With a tumor mutational burden of 3.0 and considering treatment with Atezolizumab, is it likely that this patient will respond to this therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c6eff0-ar-c6eff05.pkl. "
BLCA,3.0,0.607843137,inflamed,R,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy was used to evaluate the tumor immune microenvironment, and the tumor mutational burden is 3.0. Given this information, is treatment with atezolizumab likely to be effective?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy was used to evaluate the tumor immune microenvironment, and the tumor mutational burden is 3.0. Given this information, is treatment with atezolizumab likely to be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c919ae-ar-c919aeb.pkl. "
BLCA,11.0,1.352941176,inflamed,NR,"In a female patient with bladder urothelial carcinoma who has undergone lung biopsy for mRNA TPM expression profiling of the tumor immune microenvironment and exhibits a tumor mutational burden of 11.0, what is the likelihood of a favorable response to Atezolizumab therapy?","In a female patient with bladder urothelial carcinoma who has undergone lung biopsy for mRNA TPM expression profiling of the tumor immune microenvironment and exhibits a tumor mutational burden of 11.0, what is the likelihood of a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cabb6d-ar-cabb6d5.pkl. "
BLCA,,0.843137255,desert,NR,"I have a male patient with bladder urothelial carcinoma whose lymph node biopsy was used to measure mRNA TPM expression as a marker of the tumor immune microenvironment, but the tumor mutational burden (TMB) reading is unavailable (""nan""). Based on these findings, how likely is this patient to respond to atezolizumab?","I have a male patient with bladder urothelial carcinoma whose lymph node biopsy was used to measure mRNA TPM expression as a marker of the tumor immune microenvironment, but the tumor mutational burden (TMB) reading is unavailable (""nan""). Based on these findings, how likely is this patient to respond to atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cb132b-ar-cb132b0.pkl. "
BLCA,,,,NR,"I have a male patient with bladder urothelial carcinoma. mRNA TPM expression was measured from a liver biopsy to characterize the tumor immune microenvironment, but the tumor mutational burden is reported as ‘nan’. Based on this data, what is the likelihood that the patient will respond favorably to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma. mRNA TPM expression was measured from a liver biopsy to characterize the tumor immune microenvironment, but the tumor mutational burden is reported as ‘nan’. Based on this data, what is the likelihood that the patient will respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cc4675-ar-cc4675f.pkl. "
BLCA,26.0,4.960784314,inflamed,R,"In a female patient with bladder urothelial carcinoma who underwent a ureter biopsy for mRNA TPM expression analysis of the tumor immune microenvironment and has a tumor mutational burden of 26.0, how likely is it that she will respond favorably to Atezolizumab therapy?","In a female patient with bladder urothelial carcinoma who underwent a ureter biopsy for mRNA TPM expression analysis of the tumor immune microenvironment and has a tumor mutational burden of 26.0, how likely is it that she will respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cc7a42-ar-cc7a42d.pkl. "
BLCA,14.0,0.843137255,inflamed,NR,"I have a male patient with bladder urothelial carcinoma whose biopsy revealed specific mRNA TPM expression levels assessing the tumor immune microenvironment and a tumor mutational burden of 14. Given these findings, how likely is he to respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose biopsy revealed specific mRNA TPM expression levels assessing the tumor immune microenvironment and a tumor mutational burden of 14. Given these findings, how likely is he to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ce39dd-ar-ce39dd7.pkl. "
BLCA,,,excluded,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a lung biopsy was used to evaluate the tumor immune microenvironment, and the tumor mutational burden (TMB) is reported as nan. Considering these findings, what is the likelihood that the patient will benefit from treatment with Atezolizumab?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a lung biopsy was used to evaluate the tumor immune microenvironment, and the tumor mutational burden (TMB) is reported as nan. Considering these findings, what is the likelihood that the patient will benefit from treatment with Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cf018f-ar-cf018fe.pkl. "
BLCA,4.0,0.764705882,desert,R,"I have a female patient with bladder urothelial carcinoma (BLCA) whose mRNA TPM expression has been measured from a ureteral biopsy to evaluate her tumor immune microenvironment. With a tumor mutational burden of 4.0, would you consider her likely to respond to atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma (BLCA) whose mRNA TPM expression has been measured from a ureteral biopsy to evaluate her tumor immune microenvironment. With a tumor mutational burden of 4.0, would you consider her likely to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d02712-ar-d027124.pkl. "
BLCA,3.0,0.607843137,excluded,NR,"For a male patient with bladder urothelial carcinoma who has undergone mRNA TPM expression profiling of the tumor biopsy to evaluate the immune microenvironment and has a tumor mutational burden of 3.0, what is the anticipated response to treatment with atezolizumab?","For a male patient with bladder urothelial carcinoma who has undergone mRNA TPM expression profiling of the tumor biopsy to evaluate the immune microenvironment and has a tumor mutational burden of 3.0, what is the anticipated response to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d135d5-ar-d135d58.pkl. "
BLCA,22.0,,,NR,"For a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 22.0 and mRNA TPM expression measured from a bladder biopsy to evaluate the tumor immune microenvironment, what is the likelihood that he will respond to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 22.0 and mRNA TPM expression measured from a bladder biopsy to evaluate the tumor immune microenvironment, what is the likelihood that he will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d1bd63-ar-d1bd637.pkl. "
BLCA,,,,NR,"I have a male patient with bladder urothelial carcinoma. A bladder biopsy was performed to assess the tumor immune microenvironment via mRNA TPM expression analysis, and the tumor mutational burden (TMB) data are currently unavailable. Based on these findings, what is the likelihood that the patient will respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma. A bladder biopsy was performed to assess the tumor immune microenvironment via mRNA TPM expression analysis, and the tumor mutational burden (TMB) data are currently unavailable. Based on these findings, what is the likelihood that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d215b5-ar-d215b50.pkl. "
BLCA,3.0,0.490196078,desert,NR,"I have a female patient with bladder urothelial carcinoma who underwent a lymph node biopsy for mRNA TPM expression analysis of the tumor immune microenvironment. With a tumor mutational burden of 3.0, is Atezolizumab likely to be effective in this case?","I have a female patient with bladder urothelial carcinoma who underwent a lymph node biopsy for mRNA TPM expression analysis of the tumor immune microenvironment. With a tumor mutational burden of 3.0, is Atezolizumab likely to be effective in this case?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d2492b-ar-d2492b2.pkl. "
BLCA,62.0,10.01960784,excluded,R,"In a male patient diagnosed with bladder urothelial carcinoma, we have assessed the tumor immune microenvironment using mRNA TPM expression from a kidney biopsy, and the tumor mutational burden is 62.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","In a male patient diagnosed with bladder urothelial carcinoma, we have assessed the tumor immune microenvironment using mRNA TPM expression from a kidney biopsy, and the tumor mutational burden is 62.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d35318-ar-d353181.pkl. "
BLCA,14.0,0.784313725,excluded,R,"I have a male patient with bladder urothelial carcinoma, and we recently obtained mRNA TPM expression from a biopsy to evaluate the tumor immune microenvironment. The tumor exhibits a mutational burden of 14.0. Given these findings, would you expect him to respond favorably to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma, and we recently obtained mRNA TPM expression from a biopsy to evaluate the tumor immune microenvironment. The tumor exhibits a mutational burden of 14.0. Given these findings, would you expect him to respond favorably to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d36012-ar-d360128.pkl. "
BLCA,7.0,1.568627451,excluded,R,"A patient with bladder urothelial carcinoma underwent a lymph node biopsy for mRNA TPM assessment of the tumor immune microenvironment and has a tumor mutational burden of 7.0. Based on these data, what is the likelihood of a therapeutic response to Atezolizumab?","A patient with bladder urothelial carcinoma underwent a lymph node biopsy for mRNA TPM assessment of the tumor immune microenvironment and has a tumor mutational burden of 7.0. Based on these data, what is the likelihood of a therapeutic response to Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d3bd67-ar-d3bd679.pkl. "
BLCA,15.0,1.882352941,inflamed,R,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression was assessed from a bladder biopsy and the tumor mutational burden is 15.0. Considering these findings, is it likely that the patient will respond to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression was assessed from a bladder biopsy and the tumor mutational burden is 15.0. Considering these findings, is it likely that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d43f89-ar-d43f893.pkl. "
BLCA,5.0,0.529411765,excluded,NR,"In a male patient with bladder urothelial carcinoma, where mRNA TPM expression was analyzed from a kidney biopsy to evaluate the tumor immune microenvironment and the tumor mutational burden is 5.0, would you expect Atezolizumab to be effective?","In a male patient with bladder urothelial carcinoma, where mRNA TPM expression was analyzed from a kidney biopsy to evaluate the tumor immune microenvironment and the tumor mutational burden is 5.0, would you expect Atezolizumab to be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d4c083-ar-d4c0837.pkl. "
BLCA,,0.196078431,inflamed,NR,In a male patient with bladder urothelial carcinoma who underwent a bladder biopsy with mRNA TPM expression profiling to assess the tumor immune microenvironment—and with an indeterminate tumor mutational burden—what is the likelihood that he will benefit from treatment with Atezolizumab?,In a male patient with bladder urothelial carcinoma who underwent a bladder biopsy with mRNA TPM expression profiling to assess the tumor immune microenvironment—and with an indeterminate tumor mutational burden—what is the likelihood that he will benefit from treatment with Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d636e3-ar-d636e34.pkl. 
BLCA,,,excluded,NR,"I have a female patient with bladder urothelial carcinoma whose mRNA TPM expression was measured from a ureter biopsy to evaluate the tumor immune microenvironment, but the tumor mutational burden (TMB) data is not available. Given these factors, is she likely to respond to Atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma whose mRNA TPM expression was measured from a ureter biopsy to evaluate the tumor immune microenvironment, but the tumor mutational burden (TMB) data is not available. Given these factors, is she likely to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d697ba-ar-d697ba7.pkl. "
BLCA,24.0,,inflamed,R,"I have a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated via mRNA TPM expression from a bladder biopsy, and his tumor mutational burden is 24.0. Considering these findings, how likely is he to respond to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated via mRNA TPM expression from a bladder biopsy, and his tumor mutational burden is 24.0. Considering these findings, how likely is he to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d7d57e-ar-d7d57ee.pkl. "
BLCA,,1.411764706,desert,NR,"I have a male patient with bladder urothelial carcinoma who underwent a bladder biopsy, and we assessed the mRNA TPM expression to evaluate the tumor immune microenvironment. The reported tumor mutational burden (TMB) is ""nan."" Considering these findings, what is the likelihood that the patient will respond to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma who underwent a bladder biopsy, and we assessed the mRNA TPM expression to evaluate the tumor immune microenvironment. The reported tumor mutational burden (TMB) is ""nan."" Considering these findings, what is the likelihood that the patient will respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d86389-ar-d86389d.pkl. "
BLCA,8.0,0.725490196,desert,NR,"Considering the patient's diagnosis of bladder urothelial carcinoma, the mRNA TPM expression profile obtained from a ureter biopsy to assess the tumor immune microenvironment, and a tumor mutational burden of 8.0, how likely is it that they will respond favorably to Atezolizumab therapy?","Considering the patient's diagnosis of bladder urothelial carcinoma, the mRNA TPM expression profile obtained from a ureter biopsy to assess the tumor immune microenvironment, and a tumor mutational burden of 8.0, how likely is it that they will respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d98bac-ar-d98bac0.pkl. "
BLCA,4.0,0.274509804,,NR,"I have a male patient with bladder urothelial carcinoma who underwent a kidney biopsy for mRNA TPM expression profiling of the tumor immune microenvironment, and his tumor mutational burden is 4.0. Given these findings, would you expect him to respond favorably to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma who underwent a kidney biopsy for mRNA TPM expression profiling of the tumor immune microenvironment, and his tumor mutational burden is 4.0. Given these findings, would you expect him to respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/da4d89-ar-da4d892.pkl. "
BLCA,14.0,2.921568627,excluded,NR,"I have a male patient diagnosed with bladder urothelial carcinoma who underwent a bladder biopsy for mRNA TPM expression profiling to evaluate the tumor immune microenvironment. The tumor mutational burden is 14 mutations per megabase. Based on these factors, how likely is the patient to respond to Atezolizumab therapy?","I have a male patient diagnosed with bladder urothelial carcinoma who underwent a bladder biopsy for mRNA TPM expression profiling to evaluate the tumor immune microenvironment. The tumor mutational burden is 14 mutations per megabase. Based on these factors, how likely is the patient to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/dab9ca-ar-dab9ca8.pkl. "
BLCA,5.0,0.666666667,excluded,NR,"I am evaluating a male patient with bladder urothelial carcinoma whose tumor biopsy shows a specific mRNA TPM expression profile of the immune microenvironment and a tumor mutational burden of 5.0. Based on these findings, is the patient likely to benefit from treatment with Atezolizumab?","I am evaluating a male patient with bladder urothelial carcinoma whose tumor biopsy shows a specific mRNA TPM expression profile of the immune microenvironment and a tumor mutational burden of 5.0. Based on these findings, is the patient likely to benefit from treatment with Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/dad5c2-ar-dad5c29.pkl. "
BLCA,10.0,0.509803922,excluded,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy has been assessed to evaluate the tumor immune microenvironment. Given a tumor mutational burden of 10.0, is this patient likely to benefit from treatment with atezolizumab?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy has been assessed to evaluate the tumor immune microenvironment. Given a tumor mutational burden of 10.0, is this patient likely to benefit from treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/db3f50-ar-db3f50c.pkl. "
BLCA,,1.431372549,excluded,NR,"I have a male patient with bladder urothelial carcinoma who underwent a kidney biopsy for mRNA TPM analysis of the tumor's immune microenvironment. With the tumor mutational burden appearing unavailable, would you consider him a good candidate for treatment with atezolizumab?","I have a male patient with bladder urothelial carcinoma who underwent a kidney biopsy for mRNA TPM analysis of the tumor's immune microenvironment. With the tumor mutational burden appearing unavailable, would you consider him a good candidate for treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/dcae54-ar-dcae54f.pkl. "
BLCA,,,,NR,"In a patient with bladder urothelial carcinoma whose lymph node biopsy was used to assess mRNA TPM expression of the tumor immune microenvironment, and with an unquantifiable tumor mutational burden, how likely is it that the patient will respond to Atezolizumab therapy?","In a patient with bladder urothelial carcinoma whose lymph node biopsy was used to assess mRNA TPM expression of the tumor immune microenvironment, and with an unquantifiable tumor mutational burden, how likely is it that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/dee101-ar-dee1011.pkl. "
BLCA,19.0,3.235294118,inflamed,NR,"For a male patient diagnosed with bladder urothelial carcinoma, whose bladder biopsy analysis includes mRNA TPM expression profiling of the tumor immune microenvironment and reveals a tumor mutational burden of 19.0, what is the anticipated likelihood of a favorable response to Atezolizumab therapy?","For a male patient diagnosed with bladder urothelial carcinoma, whose bladder biopsy analysis includes mRNA TPM expression profiling of the tumor immune microenvironment and reveals a tumor mutational burden of 19.0, what is the anticipated likelihood of a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/df3e42-ar-df3e42c.pkl. "
BLCA,5.0,0.549019608,desert,NR,"Considering a female patient with bladder urothelial carcinoma who underwent a ureter biopsy for mRNA expression profiling (TPM) to assess the tumor immune microenvironment, and whose tumor mutational burden is 5 mutations per megabase, would these factors suggest that she is likely to respond to Atezolizumab therapy?","Considering a female patient with bladder urothelial carcinoma who underwent a ureter biopsy for mRNA expression profiling (TPM) to assess the tumor immune microenvironment, and whose tumor mutational burden is 5 mutations per megabase, would these factors suggest that she is likely to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e07c45-ar-e07c456.pkl. "
BLCA,2.0,,excluded,NR,"For a female patient with bladder urothelial carcinoma whose bladder biopsy demonstrated mRNA TPM expression to characterize the tumor immune microenvironment and a tumor mutational burden of 2.0, would you consider her likely to respond to Atezolizumab therapy?","For a female patient with bladder urothelial carcinoma whose bladder biopsy demonstrated mRNA TPM expression to characterize the tumor immune microenvironment and a tumor mutational burden of 2.0, would you consider her likely to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e0c49e-ar-e0c49ea.pkl. "
BLCA,14.0,2.274509804,inflamed,R,"This male patient with bladder urothelial carcinoma has a tumor mutational burden of 14.0 and mRNA TPM expression from a bladder biopsy that was evaluated to characterize the tumor immune microenvironment. Given these factors, how likely is he to respond to treatment with atezolizumab?","This male patient with bladder urothelial carcinoma has a tumor mutational burden of 14.0 and mRNA TPM expression from a bladder biopsy that was evaluated to characterize the tumor immune microenvironment. Given these factors, how likely is he to respond to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e1eb5d-ar-e1eb5d9.pkl. "
BLCA,17.0,0.862745098,inflamed,NR,"For a female patient with bladder urothelial carcinoma who underwent mRNA TPM expression profiling via nano-biopsy to assess the tumor immune microenvironment and has a TMB of 17.0 mutations/Mb, what is the likelihood that she will respond to Atezolizumab therapy?","For a female patient with bladder urothelial carcinoma who underwent mRNA TPM expression profiling via nano-biopsy to assess the tumor immune microenvironment and has a TMB of 17.0 mutations/Mb, what is the likelihood that she will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e3210d-ar-e3210d3.pkl. "
BLCA,,,,NR,"I have a male patient with bladder urothelial carcinoma. The tumor biopsy's mRNA TPM expression has been measured to assess the tumor immune microenvironment, and the tumor mutational burden is reported as ""nan."" Given these findings, how likely is it that the patient will respond favorably to atezolizumab?","I have a male patient with bladder urothelial carcinoma. The tumor biopsy's mRNA TPM expression has been measured to assess the tumor immune microenvironment, and the tumor mutational burden is reported as ""nan."" Given these findings, how likely is it that the patient will respond favorably to atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e3d426-ar-e3d4266.pkl. "
BLCA,6.0,0.470588235,excluded,NR,"I have a male patient with bladder urothelial carcinoma. His tumor's mRNA TPM expression was evaluated from a biopsy to assess the immune microenvironment, and his tumor mutational burden is 6.0 mutations/Mb. Based on these factors, what is the likelihood that he will respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma. His tumor's mRNA TPM expression was evaluated from a biopsy to assess the immune microenvironment, and his tumor mutational burden is 6.0 mutations/Mb. Based on these factors, what is the likelihood that he will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e41b1e-ar-e41b1e7.pkl. "
BLCA,9.0,2.176470588,desert,R,"In a female patient with bladder urothelial carcinoma, the tumor's mRNA TPM expression was assessed from a bladder biopsy and a tumor mutational burden of 9.0 was noted. Given these molecular characteristics, would you expect a favorable response to Atezolizumab therapy?","In a female patient with bladder urothelial carcinoma, the tumor's mRNA TPM expression was assessed from a bladder biopsy and a tumor mutational burden of 9.0 was noted. Given these molecular characteristics, would you expect a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e50d15-ar-e50d15f.pkl. "
BLCA,5.0,0.098039216,excluded,NR,"I have a female patient with bladder urothelial carcinoma whose mRNA TPM expression was evaluated using a kidney biopsy to assess the tumor immune microenvironment. With a tumor mutational burden of 5.0, what is the likelihood of response to Atezolizumab in this case?","I have a female patient with bladder urothelial carcinoma whose mRNA TPM expression was evaluated using a kidney biopsy to assess the tumor immune microenvironment. With a tumor mutational burden of 5.0, what is the likelihood of response to Atezolizumab in this case?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e56c96-ar-e56c96c.pkl. "
BLCA,5.0,0.274509804,excluded,NR,"In a male patient with bladder urothelial carcinoma, a liver biopsy provided mRNA TPM expression data for evaluating the tumor immune microenvironment, and the tumor mutational burden is 5.0 mutations per megabase. Based on these findings, how likely is the patient to respond to atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, a liver biopsy provided mRNA TPM expression data for evaluating the tumor immune microenvironment, and the tumor mutational burden is 5.0 mutations per megabase. Based on these findings, how likely is the patient to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e5bc41-ar-e5bc417.pkl. "
BLCA,,,desert,R,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy was used to assess the tumor immune microenvironment, but the tumor mutational burden (TMB) is unavailable. Based on these findings, how likely is the patient to benefit from atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy was used to assess the tumor immune microenvironment, but the tumor mutational burden (TMB) is unavailable. Based on these findings, how likely is the patient to benefit from atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e71235-ar-e712352.pkl. "
BLCA,,,,NR,"I have a male patient with bladder urothelial carcinoma. We measured mRNA TPM expression from a kidney biopsy to evaluate the tumor immune microenvironment, but the tumor mutational burden (TMB) is not available. Considering these factors, how likely is it that he will respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma. We measured mRNA TPM expression from a kidney biopsy to evaluate the tumor immune microenvironment, but the tumor mutational burden (TMB) is not available. Considering these factors, how likely is it that he will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e7bcab-ar-e7bcab0.pkl. "
BLCA,7.0,1.37254902,inflamed,NR,"I am managing a male patient with bladder urothelial carcinoma whose mRNA TPM expression from a kidney biopsy was analyzed to evaluate the tumor immune microenvironment. With a tumor mutational burden of 7.0, how likely is it that he will respond to Atezolizumab therapy?","I am managing a male patient with bladder urothelial carcinoma whose mRNA TPM expression from a kidney biopsy was analyzed to evaluate the tumor immune microenvironment. With a tumor mutational burden of 7.0, how likely is it that he will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e7bf6c-ar-e7bf6c0.pkl. "
BLCA,1.0,0.196078431,inflamed,NR,"I have a male patient with bladder urothelial carcinoma who underwent a bladder biopsy for mRNA TPM expression profiling to assess the tumor immune microenvironment, and his tumor mutational burden (TMB) is 1.0. Based on this information, do you anticipate that he is likely to respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma who underwent a bladder biopsy for mRNA TPM expression profiling to assess the tumor immune microenvironment, and his tumor mutational burden (TMB) is 1.0. Based on this information, do you anticipate that he is likely to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e7e4f7-ar-e7e4f7c.pkl. "
BLCA,,,excluded,NR,"For a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy has been used to evaluate the tumor immune microenvironment, although the tumor mutational burden (TMB) data is not available. Based on these findings, how likely is it that the patient will respond to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy has been used to evaluate the tumor immune microenvironment, although the tumor mutational burden (TMB) data is not available. Based on these findings, how likely is it that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e9475f-ar-e9475f7.pkl. "
BLCA,6.0,1.019607843,excluded,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy has been evaluated for insights into the tumor immune microenvironment, and the tumor mutational burden is 6.0. Given these findings, what is the likelihood that he will respond to treatment with atezolizumab?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy has been evaluated for insights into the tumor immune microenvironment, and the tumor mutational burden is 6.0. Given these findings, what is the likelihood that he will respond to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e94c30-ar-e94c30c.pkl. "
BLCA,3.0,0.705882353,excluded,NR,"I have a female patient with bladder urothelial carcinoma whose tumor immune microenvironment was assessed via mRNA TPM expression from a bladder biopsy, and her tumor mutational burden is 3.0. Based on these findings, what is the likelihood that she will respond favorably to Atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma whose tumor immune microenvironment was assessed via mRNA TPM expression from a bladder biopsy, and her tumor mutational burden is 3.0. Based on these findings, what is the likelihood that she will respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e97af0-ar-e97af0f.pkl. "
BLCA,7.0,1.333333333,desert,NR,"In a male patient with bladder urothelial carcinoma, a bladder biopsy revealed mRNA TPM expression levels indicative of the tumor immune microenvironment and a tumor mutational burden of 7.0 mutations per megabase. Given these factors, what is the likelihood that the patient will respond favorably to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, a bladder biopsy revealed mRNA TPM expression levels indicative of the tumor immune microenvironment and a tumor mutational burden of 7.0 mutations per megabase. Given these factors, what is the likelihood that the patient will respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e9ae8b-ar-e9ae8be.pkl. "
BLCA,14.0,2.764705882,inflamed,R,"For a patient with bladder urothelial carcinoma whose biopsy analysis shows mRNA TPM expression indicative of the tumor immune microenvironment and a tumor mutational burden of 14.0, what is the likelihood of a favorable response to Atezolizumab therapy?","For a patient with bladder urothelial carcinoma whose biopsy analysis shows mRNA TPM expression indicative of the tumor immune microenvironment and a tumor mutational burden of 14.0, what is the likelihood of a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/eaa477-ar-eaa477a.pkl. "
BLCA,2.0,0.058823529,excluded,NR,"For a male patient with bladder urothelial carcinoma and a tumor mutational burden of 2.0, mRNA TPM expression data were obtained via a kidney biopsy to assess the tumor immune microenvironment. Based on these factors, how likely is the patient to respond to atezolizumab therapy?","For a male patient with bladder urothelial carcinoma and a tumor mutational burden of 2.0, mRNA TPM expression data were obtained via a kidney biopsy to assess the tumor immune microenvironment. Based on these factors, how likely is the patient to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/eb2962-ar-eb29625.pkl. "
BLCA,,,,NR,"A male patient with bladder urothelial carcinoma has undergone mRNA TPM expression profiling from a bladder biopsy to assess his tumor immune microenvironment, and his tumor mutational burden is reported as ""nan."" Based on these findings, how likely is it that he will respond to Atezolizumab therapy?","A male patient with bladder urothelial carcinoma has undergone mRNA TPM expression profiling from a bladder biopsy to assess his tumor immune microenvironment, and his tumor mutational burden is reported as ""nan."" Based on these findings, how likely is it that he will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/eb587a-ar-eb587a6.pkl. "
BLCA,,,,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a lymph node biopsy was used to assess the tumor immune microenvironment, although tumor mutational burden (TMB) data is not available. How should we interpret these findings in relation to his potential response to atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a lymph node biopsy was used to assess the tumor immune microenvironment, although tumor mutational burden (TMB) data is not available. How should we interpret these findings in relation to his potential response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ee3844-ar-ee3844c.pkl. "
BLCA,1.0,0.039215686,inflamed,NR,"I have a male patient with bladder urothelial carcinoma. The tumor mutational burden is 1.0, and mRNA TPM expression from a lung biopsy was used to assess the tumor immune microenvironment. Based on these findings, what is the likelihood of this patient responding to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma. The tumor mutational burden is 1.0, and mRNA TPM expression from a lung biopsy was used to assess the tumor immune microenvironment. Based on these findings, what is the likelihood of this patient responding to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ef0e3d-ar-ef0e3d2.pkl. "
BLCA,14.0,,desert,NR,"My patient with bladder urothelial carcinoma (BLCA) underwent a ureter biopsy for mRNA TPM expression analysis to evaluate the tumor immune microenvironment, and the tumor exhibits a mutational burden (TMB) of 14.0. Would these findings support a favorable response to Atezolizumab therapy?","My patient with bladder urothelial carcinoma (BLCA) underwent a ureter biopsy for mRNA TPM expression analysis to evaluate the tumor immune microenvironment, and the tumor exhibits a mutational burden (TMB) of 14.0. Would these findings support a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/eff2ce-ar-eff2ce3.pkl. "
BLCA,14.0,1.098039216,inflamed,NR,"We have a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 14.0. Additionally, mRNA TPM expression from a kidney biopsy was used to assess the tumor immune microenvironment. Given these findings, what is the likelihood that the patient will respond well to Atezolizumab therapy?","We have a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 14.0. Additionally, mRNA TPM expression from a kidney biopsy was used to assess the tumor immune microenvironment. Given these findings, what is the likelihood that the patient will respond well to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f20b82-ar-f20b827.pkl. "
BLCA,9.0,,excluded,R,"I have a male patient with bladder urothelial carcinoma. His bladder biopsy shows mRNA TPM expression profiling to assess the tumor immune microenvironment, and his tumor mutational burden is 9.0. Based on these findings, what is the likelihood that he will respond favorably to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma. His bladder biopsy shows mRNA TPM expression profiling to assess the tumor immune microenvironment, and his tumor mutational burden is 9.0. Based on these findings, what is the likelihood that he will respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f275eb-ar-f275eb8.pkl. "
BLCA,8.0,,desert,NR,"I have a male patient with bladder urothelial carcinoma whose tumor mRNA expression was evaluated from a bladder biopsy to assess the immune microenvironment. The tumor mutational burden is 8.0 mutations per megabase. Based on this information, is he likely to respond favorably to atezolizumab?","I have a male patient with bladder urothelial carcinoma whose tumor mRNA expression was evaluated from a bladder biopsy to assess the immune microenvironment. The tumor mutational burden is 8.0 mutations per megabase. Based on this information, is he likely to respond favorably to atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f28c01-ar-f28c015.pkl. "
BLCA,7.0,0.803921569,desert,NR,"I have a female patient with bladder urothelial carcinoma (BLCA) whose bladder biopsy showed specific mRNA TPM expression levels to assess the tumor immune microenvironment, and her tumor mutational burden is 7.0. Based on these findings, what is her likelihood of responding to Atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma (BLCA) whose bladder biopsy showed specific mRNA TPM expression levels to assess the tumor immune microenvironment, and her tumor mutational burden is 7.0. Based on these findings, what is her likelihood of responding to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f2aae1-ar-f2aae14.pkl. "
BLCA,4.0,,excluded,NR,"In a female patient with bladder urothelial carcinoma who has a tumor mutational burden of 4.0 and whose mRNA TPM expression from a kidney biopsy has been used to evaluate the tumor immune microenvironment, would you anticipate that Atezolizumab would be an effective therapeutic option?","In a female patient with bladder urothelial carcinoma who has a tumor mutational burden of 4.0 and whose mRNA TPM expression from a kidney biopsy has been used to evaluate the tumor immune microenvironment, would you anticipate that Atezolizumab would be an effective therapeutic option?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f3a9bc-ar-f3a9bce.pkl. "
BLCA,7.0,0.529411765,desert,NR,"In a male patient with bladder urothelial carcinoma, where the tumor immune microenvironment was evaluated using mRNA TPM expression from a kidney biopsy and the tumor mutational burden is 7.0, is there evidence to suggest that treatment with atezolizumab would be effective?","In a male patient with bladder urothelial carcinoma, where the tumor immune microenvironment was evaluated using mRNA TPM expression from a kidney biopsy and the tumor mutational burden is 7.0, is there evidence to suggest that treatment with atezolizumab would be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f82bbd-ar-f82bbdc.pkl. "
BLCA,,5.921568627,inflamed,R,For a male patient with bladder urothelial carcinoma whose mRNA TPM expression from a bladder biopsy was used to evaluate the tumor immune microenvironment—and with tumor mutational burden data currently unavailable—how likely is it that the patient will respond to Atezolizumab therapy?,For a male patient with bladder urothelial carcinoma whose mRNA TPM expression from a bladder biopsy was used to evaluate the tumor immune microenvironment—and with tumor mutational burden data currently unavailable—how likely is it that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/fb7aec-ar-fb7aec7.pkl. 
BLCA,5.0,,desert,NR,"I have a male patient with bladder urothelial carcinoma whose tumor biopsy reveals an mRNA expression profile of the immune microenvironment and a tumor mutational burden of 5.0. Based on these findings, how likely is he to respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose tumor biopsy reveals an mRNA expression profile of the immune microenvironment and a tumor mutational burden of 5.0. Based on these findings, how likely is he to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/fd9476-ar-fd94761.pkl. "
BLCA,7.0,0.352941176,desert,NR,"In a female patient with bladder urothelial carcinoma, whose bladder biopsy revealed specific mRNA TPM expression levels and a tumor mutational burden of 7.0, what is the likelihood of a favorable response to Atezolizumab therapy based on these biomarkers?","In a female patient with bladder urothelial carcinoma, whose bladder biopsy revealed specific mRNA TPM expression levels and a tumor mutational burden of 7.0, what is the likelihood of a favorable response to Atezolizumab therapy based on these biomarkers?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/fed609-ar-fed6099.pkl. "
BLCA,10.0,,desert,R,"I have a patient with bladder urothelial carcinoma whose tumor microenvironment was characterized using mRNA TPM expression from a prior biopsy, and the tumor mutational burden is 10.0 mutations per megabase. Based on these factors, do you expect that the patient will have a favorable response to atezolizumab?","I have a patient with bladder urothelial carcinoma whose tumor microenvironment was characterized using mRNA TPM expression from a prior biopsy, and the tumor mutational burden is 10.0 mutations per megabase. Based on these factors, do you expect that the patient will have a favorable response to atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ffa5c7-ar-ffa5c7c.pkl. "
